04/18/2024 | Press release | Distributed by Public on 04/18/2024 04:04
☐
|
Preliminary Proxy Statement
|
☐
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
☒
|
Definitive Proxy Statement
|
☐
|
Definitive Additional Materials
|
☐
|
Soliciting Material under §240.14a-12
|
☒
|
No fee required.
|
☐
|
Fee paid previously with preliminary materials.
|
☐
|
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
Table of Contents
|
Table of Contents
|
Stelios Papadopoulos, Ph.D.
Chair of the Board
|
Julie Anne Smith
Chair of the Compensation Committee
|
Table of Contents
|
Table of Contents
|
Important notice regarding the availability of proxy materials for the 2024 Annual Meeting of Stockholders to be
held on May 30, 2024, at 9:00 a.m., Pacific Time, via live webcast at www.virtualshareholdermeeting.com/
EXEL2024. You will need your 16-digit control number provided on your Notice of Internet Availability of Proxy
Materials, your proxy card or your voting instruction form to gain access to the virtual Annual Meeting.
The Proxy Statement and Annual Report to stockholders are available at www.exel-
annualstockholdermeeting.com.
The Board of Directors recommends that you vote "FOR" Proposal Nos. 1-4 identified above.
|
Table of Contents
|
1.To elect the eleven nominees for director named in the Proxy Statement accompanying this Notice of Annual
Meeting to hold office until the next annual meeting of stockholders and until his or her successor is duly elected
and qualified or until his or her death, resignation or removal.
|
2.To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Exelixis'
independent registered public accounting firm for the fiscal year ending January 3, 2025.
|
3.To amend and restate the Exelixis, Inc. 2000 Employee Stock Purchase Plan to, among other things, increase the
number of shares authorized for issuance by 6,000,000 shares.
|
4.To approve, on an advisory basis, the compensation of Exelixis' Named Executive Officers, as disclosed in the
Proxy Statement accompanying this Notice of Annual Meeting.
|
5.To conduct any other business properly brought before the meeting.
|
Important notice regarding the availability of proxy materials for the 2024 Annual Meeting of Stockholders to be
held on May 30, 2024, at 9:00 a.m., Pacific Time, via live webcast atwww.virtualshareholdermeeting.com/
EXEL2024. You will need your 16-digit control number provided on your Notice of Internet Availability of Proxy
Materials, your proxy card or your voting instruction form to gain access to the virtual Annual Meeting.
The Proxy Statement and Annual Report to stockholders are available at www.exel-
annualstockholdermeeting.com.
|
Table of Contents
|
Questions and Answers about these Proxy Materials and Voting
|
1
|
Proposal 1: Election of Directors
|
9
|
Director Nominees
|
13
|
Board Committees
|
20
|
Audit Committee
|
20
|
Compensation Committee
|
22
|
Governance Committee
|
22
|
Research & Development Committee
|
23
|
Risk Committee
|
24
|
Meetings and Attendance
|
24
|
Corporate Governance
|
25
|
Compensation of Directors
|
31
|
Director Compensation Table
|
34
|
Proposal 2: Ratification of Selection of Independent Registered Public Accounting Firm
|
36
|
Report of the Audit Committee
|
38
|
Proposal 3: Amendment and Restatement of the Exelixis, Inc. 2000 Employee Stock Purchase Plan
|
39
|
Proposal 4: Advisory Vote on the Compensation of the Named Executive Officers
|
46
|
Required Vote and Board of Directors Recommendation
|
46
|
Security Ownership of Certain Beneficial Owners and Management
|
47
|
Information about our Executive Officers
|
50
|
Compensation of Executive Officers
|
52
|
Compensation Discussion and Analysis
|
52
|
Executive Summary
|
52
|
How We Determine Executive Compensation
|
57
|
Compensation Elements
|
60
|
Compensation Mix
|
62
|
2023 Compensation Decisions
|
62
|
Other Compensation Information
|
72
|
Compensation Policies and Practices as They Relate to Risk Management
|
74
|
Summary of Compensation
|
75
|
Grants of Plan-Based Awards
|
78
|
Compensation Arrangements
|
80
|
Outstanding Equity Awards at Fiscal Year-End
|
81
|
Option Exercises and Stock Vested
|
84
|
Potential Payments Upon Termination or Change in Control
|
84
|
CEO Pay Ratio
|
88
|
Pay Versus Performance
|
89
|
Compensation Committee Report
|
94
|
Compensation Committee Interlocks and Insider Participation
|
94
|
Certain Relationships and Related Party Transactions
|
94
|
Householding of Proxy Materials
|
95
|
Annual Report on Form 10-K
|
95
|
Other Matters
|
95
|
Appendix A
|
A-1
|
Table of Contents
|
i
|
Exelixis, Inc.
|
Table of Contents
|
Proxy Statement |Questions and Answers
|
2024 Proxy Statement
|
1
|
Table of Contents
|
2
|
Exelixis, Inc.
|
At Virtual
Meeting
|
››To vote at the Annual Meeting, follow the instructions at www.virtualshareholdermeeting.com/
EXEL2024. You will need your 16-digit control number provided on your Notice of Availability, your
proxy card or your voting instruction form to gain access to the Annual Meeting.
|
Via Internet
|
››To vote on the Internet, go to www.proxyvote.com and follow the instructions provided in the Notice
of Availability. You will need your 16-digit control number provided on your Notice of Availability,
your proxy card or your voting instruction form to vote your shares in advance of the meeting. Your
vote must be received by 11:59 p.m., Eastern Time, on May 29, 2024, to be counted.
|
By Telephone
|
››To vote by telephone, follow the instructions and call the number provided in the proxy materials
to transmit your voting instructions. Your vote must be received by 11:59 p.m. Eastern Time, on
May 29, 2024, to be counted.
|
By Mail
|
››To vote by mail, follow the instructions provided in the proxy materials, request a paper copy of the
proxy materials and then complete, sign and date the proxy card enclosed with the paper copy of the
proxy materials and return it promptly in the envelope that will be provided. If you return your
signed proxy card to us before the Annual Meeting, we will vote your shares as you direct.
|
Table of Contents
|
Proxy Statement |Questions and Answers
|
2024 Proxy Statement
|
3
|
We provide Internet proxy voting to allow you to vote your shares online, with procedures designed to ensure
the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear
any costs associated with your Internet access, such as usage charges from Internet access providers and
telephone companies.
|
Table of Contents
|
4
|
Exelixis, Inc.
|
Table of Contents
|
Proxy Statement |Questions and Answers
|
2024 Proxy Statement
|
5
|
Table of Contents
|
6
|
Exelixis, Inc.
|
Table of Contents
|
Proxy Statement |Questions and Answers
|
2024 Proxy Statement
|
7
|
Table of Contents
|
8
|
Exelixis, Inc.
|
Proposal Snapshot - Item 1. Election of Directors
What is being voted on:Election of 11 director nominees to our Board.
Board recommendation:After a review of the individual qualifications and experience of each of our director
nominees and his or her contributions to our Board (as applicable), our Board determined unanimously to
recommend that shareholders vote FOR all of our director nominees.
|
Table of Contents
|
Proposal 1 |Election of Directors
|
2024 Proxy Statement
|
9
|
Director Nominees
|
Age
|
Position
|
Director
Since
|
Mary C. Beckerle, Ph.D.
|
69
|
Independent Director
|
2024
|
S. Gail Eckhardt, M.D.
|
66
|
Independent Director
|
2024
|
Maria C. Freire, Ph.D.
|
69
|
Independent Director
|
2018
|
Tomas J. Heyman
|
68
|
Independent Director
|
2023
|
David E. Johnson
|
41
|
Independent Director
|
2023
|
Michael M. Morrissey, Ph.D.
|
63
|
President and Chief Executive Officer
|
2010
|
Robert L. Oliver, Jr.
|
65
|
Independent Director
|
2023
|
Stelios Papadopoulos, Ph.D.
|
75
|
Independent Chair of the Board
|
1994
|
George Poste, DVM, Ph.D., FRS
|
79
|
Independent Director
|
2004
|
Julie Anne Smith
|
53
|
Independent Director
|
2016
|
Jack L. Wyszomierski
|
68
|
Independent Director
|
2004
|
Table of Contents
|
10
|
Exelixis, Inc.
|
Table of Contents
|
Proposal 1 |Election of Directors
|
2024 Proxy Statement
|
11
|
10 of 11 Director Nominees are Independent
Our Board determined that each of our director nominees (other than Dr. Morrissey) is "independent" within the
meaning of applicable SEC rules and regulations and the Nasdaq listing standards. Dr. Garber and Ms. Wright, who
are not standing for re-election at our 2024 Annual Meeting, and Drs. Marchesi and Willsey and Mr. Feldbaum,
each of whom served as directors for part of 2023 before their respective departures from the Board, were also
determined to be independent. In addition, the Board determined that: (i) all directors who serve on the Audit,
Compensation and Governance Committees are independent under applicable Nasdaq listing standards; and (ii) all
members of the Audit Committee meet the independence requirements under the Exchange Act.
|
Table of Contents
|
12
|
Exelixis, Inc.
|
Director Nominees
|
|
Mary C. Beckerle, Ph.D.
Chief Executive Officer, Huntsman Cancer Institute at the University
of Utah
|
Director since 2024
Age 69
Key Qualifications and Expertise:
Our Board concluded that Dr. Beckerle should
continue to serve as a director of Exelixis due to her
training as a scientist, her extensive knowledge and
experience in the field of cancer research and
treatment, and her broad leadership experience, in
particular her corporate governance experience,
resulting from managing a world-class healthcare
organization and service on various public company
boards and scientific or advisory boards.
Committee Assignments:
•Governance Committee
•Research & Development Committee
Other Current Public Company Boards:
•Huntsman Corporation, serving on the
Nominating and Corporate Governance
Committee and Sustainability Committee
•Johnson & Johnson, serving on the Regulatory
Compliance & Sustainability Committee and
Science & Technology Committee (Chair)
|
Mary C. Beckerle, Ph.D., has been a director since January 2024. Since 2006,
Dr. Beckerle has served as Chief Executive Officer of the Huntsman Cancer Institute at
the University of Utah, and is also currently serving as Associate Vice President for
Cancer Affairs and a Distinguished Professor of Biology and Oncological Sciences at the
University of Utah. She first joined the faculty of the University of Utah in 1986,
serving in numerous research and leadership positions over the years, and currently
holds the Jon M. Huntsman Presidential Endowed Chair. Dr. Beckerle has served as a
member of the board of directors of Huntsman Corporation, a publicly held global
manufacturer of specialty chemicals, since 2011, and as a member of the board of
directors of Johnson & Johnson, a publicly held diversified healthcare company, since
2015. She has been named a National Association of Corporate Directors (NACD)
Corporate Governance Fellow and was a 2018 NACD Directorship 100 Honoree. In
addition, she currently serves on a number of scientific and other advisory boards,
including the Medical Advisory Board of the Howard Hughes Medical Institute since
2015, as well as on various external advisory boards of National Cancer Institute-
designated cancer centers. Previously, Dr. Beckerle served as a member of the Board
of Scientific Advisors of the National Cancer Institute from 2018 to 2022, the External
Advisory Board of the Dana-Farber/Harvard Cancer Center from 2013 to 2022, the
Board of Directors of the American Association for Cancer Research from 2013 to
2016, the American Cancer Society Council for Extramural Grants from 2008 to 2012
(serving as Chair from 2010 to 2012) and the National Institute of Health's Advisory
Committee to the Director from 2007 to 2010, as well as President of the American
Society for Cell Biology from 2006 to 2007. She is also an elected member of the
National Academy of Sciences, the American Philosophical Society and the American
Academy of Arts and Sciences. Dr. Beckerle holds a B.A. in Biology and Psychology
(magna cum laude) from Wells College and a Ph.D. in Molecular, Cellular and
Developmental Biology from the University of Colorado, Boulder. She completed her
post-doctoral fellowship in Anatomy and Cell Biology at the University of North
Carolina at Chapel Hill.
|
|
Table of Contents
|
Proposal 1 | Director Nominees
|
2024 Proxy Statement
|
13
|
S. Gail Eckhardt, M.D.
Professor and Associate Dean of Experimental Therapeutics,
Associate Director of Translational Research, Dan L. Duncan
Comprehensive Cancer Center, at Baylor College of Medicine
|
Director since 2024
Age 66
Key Qualifications and Expertise:
Our Board concluded that Dr. Eckhardt should
continue to serve as a director of Exelixis due to her
skills as a physician and medical researcher, and her
leadership experience in drug development and
translational medicine relative to oncology, as well as
her service on various public company boards and
scientific or advisory boards.
Committee Assignments:
•Compensation Committee
•Research & Development Committee
Other Current Public Company Boards:
•Syros Pharmaceuticals, Inc., serving on the
Compensation Committee and the Nominating
and Corporate Governance Committee
|
S. Gail Eckhardt, M.D., has been a director since January 2024. Since September 2023,
Dr. Eckhardt has served as Professor and Associate Dean of Experimental Therapeutics
at Baylor College of Medicine, as well as Associate Director of Translational Research
at the Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine.
Between 2017 and 2023, she was a tenured professor at Dell Medical School at the
University of Texas at Austin, where she also served as Chair of the Department of
Oncology, Associate Dean of Cancer Programs and as the inaugural Director of the
Livestrong Cancer Institutes. Prior to joining the University of Texas, Dr. Eckhardt was a
member of the faculty at the University of Colorado School of Medicine from 1999 to
2017 (receiving tenure in 2001), where she had numerous roles and responsibilities,
including Division Head of Medical Oncology, Associate Director for Translational
Research at the University of Colorado Comprehensive Cancer Center and Director of
the Phase I Program and Fellowship. Dr. Eckhardt has served as a member of the
board of directors of Syros Pharmaceuticals, Inc., a publicly held biopharmaceutical
company focused on developing frontline treatments for patients with hematologic
malignancies, since September 2020. In addition, she has served on numerous
committees and study sections, including the American Society of Clinical Oncology's
Molecular Oncology Task Force and Board of Directors, the U.S. Food and Drug
Administrations' Oncology Drugs Advisory Committee and the National Cancer
Institute's Cancer Centers Study Section and Investigational Drug Steering Committee,
as well as eleven external advisory boards of National Cancer Institute-designated
cancer centers. Dr. Eckhardt is also a current member of the National Academies
Cancer Policy Forum and was previously a lead mentor in the American Society of
Clinical Oncology's Leadership Development Program and a member of the board of
directors of the Association of American Cancer Institutes. Dr. Eckhardt holds a B.S. in
Chemistry from Stephen F. Austin State University and an M.D. from the University of
Texas Medical Branch in Galveston. She conducted her internship and residency in
Internal Medicine at the University of Virginia Medical School, followed by a
post-doctoral research fellowship in Experimental and Molecular Medicine at Scripps
Research Institute in La Jolla, California and a fellowship in Medical Oncology at the
University of California, San Diego.
|
|
Maria C. Freire, Ph.D.
Former President and Executive Director, Foundation for the
National Institutes of Health
|
Director since 2018
Age 69
Key Qualifications and Expertise:
Our Board concluded that Dr. Freire should continue
to serve as a director of Exelixis due to her training as
a scientist, her knowledge and experience with respect
to U.S. and global public health, the biopharmaceutical
industry and government healthcare policymaking, as
well as her leadership experience in the public sector.
Committee Assignments:
•Governance Committee (Chair Elect)
•Research & Development Committee
Other Current Public Company Boards:
•Alexandria Real Estate Equities, serving on the
Nominating & Corporate Governance
Committee and the Science & Technology
Committee (Chair)
•Biogen Inc., serving on the Compensation and
Management Development Committee
|
Maria C. Freire, Ph.D., has been a director since April 2018. From 2012 to 2021,
Dr. Freire served as President and Executive Director and as a member of the board of
directors of the Foundation for the National Institutes of Health. Previously, she
served as President and as a member of the board of directors of the Albert and Mary
Lasker Foundation from 2008 to 2012, as President and Chief Executive Officer of the
Global Alliance for TB Drug Development from 2011 to 2008 and as Director of the
Office of Technology Transfer at the National Institutes of Health from 1995 to 2001.
Dr. Freire has served on the board of directors of Biogen Inc., a publicly held
biopharmaceutical company focused on the treatment of serious diseases, since 2021,
on the board of directors of Alexandria Real Estate Equities, Inc., a publicly held urban
office real estate investment trust uniquely focused on collaborative life science and
technology campuses, since 2012, and on the board of directors of Koneksa Health, a
private digital biomarker company, since 2022. She has previously served on the
boards of numerous national and international organizations, including the Science
Board of the U.S. Food and Drug Administration, the World Health Organization
Commission on Intellectual Property Rights, Innovation and Public Health and the
United Nations Secretary General's High Level Panel on Access to Medicines. Dr. Freire
is also a member of the National Academy of Medicine and the Council on Foreign
Relations, and she is the recipient of numerous awards, including a 2017 Gold Stevie
Award for "Woman of the Year," the U.S. Department of Health and Human Services
Secretary's Award for Distinguished Service, the Arthur S. Fleming Award and the
Bayh-Dole Award. Dr. Freire holds a Ph.D. in Biophysics from the University of Virginia
and a B.S. from the Universidad Peruana Cayetano Heredia in Lima, Peru.
|
|
Table of Contents
|
14
|
Exelixis, Inc.
|
Tomas J. Heyman
Consultant and Interim Chief Executive Officer, Interlaken
Therapeutics, Inc.
|
Director since 2023
Age 68
Key Qualifications and Expertise:
Our Board concluded that Mr. Heyman should
continue to serve as a director of Exelixis due to his
expertise in corporate development and his significant
leadership experience in the biopharmaceutical sector,
as well as his extensive experience serving on the
boards of several public and private companies.
Committee Assignments:
•Governance Committee
•Risk Committee (Chair Elect)
Other Current Public Company Boards:
•Akero Therapeutics, Inc., serving on the Audit
Committee and Nominating and Corporate
Governance Committee (Chair)
•OptiNose, Inc., serving on the Nominating and
Corporate Governance Committee
•Invivyd, Inc., serving on the Audit Committee
and Compensation Committee (Chair) (and has
announced his intention not to seek re-election
in 2024)
•Legend Biotech Corporation
•Xilio Therapeutics, Inc., serving on the Audit
Committee and Nominating and Corporate
Governance Committee (Chair) (and has
announced his intention not to seek re-election
in 2024)
|
Tomas J. Heyman has been a director since May 2023. Since 2021, Mr. Heyman has
served as a consultant to Interlaken Therapeutics, Inc., a biotechnology company, and
as its interim Chief Executive Officer, and since 2020, he has served as Operating
Partner at Bioqube Ventures, a life sciences investment firm. Previously, Mr. Heyman
served as the President of Johnson & Johnson's Corporate Venture Capital Group, the
venture capital arm of Johnson & Johnson, a pharmaceutical and consumer packaged
goods company, from 2015 to 2019, and as the Global Head of Business Development
for Johnson & Johnson's Pharmaceutical Group from 1992 to 2015. In addition, he
served as Managing Director of Janssen Pharmaceutica, a pharmaceutical NV, a
pharmaceutical company and an affiliate of Johnson & Johnson (now known as
Johnson & Johnson Innovative Medicine), from 2008 to 2016. Mr. Heyman began his
career as a member of the legal department of Janssen Pharmaceutica NV in 1982.
Mr. Heyman has served as Non-executive Chairman of the board of directors of
Venatorx Pharmaceuticals, Inc., a privately held pharmaceutical company, since 2023.
He has also served as a member of the board of directors of: Legend Biotech
Corporation, a publicly held biotechnology company, since 2022; Xilio Therapeutics,
Inc., a publicly held biotechnology company, since 2022 (and has announced his
intention to not seek re-election in 2024); Invivyd, Inc. (formerly Adagio Therapeutics),
a publicly held biopharmaceutical company, since 2021 (and has announced his
intention to not seek re-election in 2024); OptiNose, Inc., a publicly held specialty
pharmaceutical company, since 2020; and Akero Therapeutics, Inc., a publicly held
biotechnology company, since 2020. Previously, Mr. Heyman served as a member of
the Supervisory Board of Crucell NV, a biotechnology company. In addition to his
private and public company experience, Mr. Heyman has served on the board of
directors of the International Biomedical Research Alliance, a non-profit organization
focused on biomedical research, since 2018, and as a member of the board of
directors of Interuniversitair Micro-Electronica Centrum VZW, a Belgian non-profit
organization specializing in micro- and nano-electronic research, since 2012.
Mr. Heyman holds a Master of Laws from Katholieke Universiteit Leuven.
He continued with post-graduate studies in International Law in Geneva, Switzerland,
and post-graduate studies in Business Management at the University of Antwerp
in Belgium.
|
|
David E. Johnson
Managing Partner and Chief Investment Officer, Caligan Partners LP
|
Director since 2023
Age 41
Key Qualifications and Expertise:
Our Board concluded that Mr. Johnson should
continue to serve as a director at Exelixis due to his
expertise in strategic capital allocation and experience
as an investor and director for various life
sciences companies.
Committee Assignments:
•Audit Committee
•Research & Development Committee
Other Current Public Company Boards:
•Liquidia Corporation, serving on the
Audit Committee
|
David E. Johnson has been a director since May 2023. Since 2017, Mr. Johnson has
served as the Managing Partner and Chief Investment Officer of Caligan Partners LP,
an SEC-registered investment adviser. Previously, he served as Managing Director at
the Carlyle Group, a global private equity, alternative asset management and financial
services firm, from 2010 to 2017, and as Vice President in the Principal Investments
area at Morgan Stanley, a global financial services and investment management firm,
from 2004 to 2010. Prior to joining Morgan Stanley, Mr. Johnson worked at Weiss
Asset Management, an investment management firm, from 2003 to 2004. Mr. Johnson
has served as a member of the board of directors of Liquidia Corporation, a publicly
held biopharmaceutical company, since 2021, and as a member of the board of
directors of AMAG Pharmaceuticals, Inc., a publicly held pharmaceutical company
specializing in products treating iron deficiency anemia, from 2019 until its acquisition
by Covis Group S.à r.l. in 2020. In the not-for-profit sector, Mr. Johnson serves as a
member of the board of directors of The Children's Scholarship Fund, Inc., a privately
funded tuition assistance program, and previously served on the Executive Committee
for the Harvard College Fund. Mr. Johnson holds an A.B. and S.M. in Applied
Mathematics from Harvard University.
|
|
Table of Contents
|
Proposal 1 | Director Nominees
|
2024 Proxy Statement
|
15
|
Michael M. Morrissey, Ph.D.
President and Chief Executive Officer, Exelixis, Inc.
|
Director since 2010
Age 63
Key Qualifications and Expertise:
Our Board concluded that Dr. Morrissey should
continue to serve as a director of Exelixis due to his
leadership role as the President and Chief Executive
Officer of Exelixis. Beyond his role as Exelixis' principal
executive officer, the Board also considered
Dr. Morrissey's extensive qualifications, including his
training as a scientist, his significant knowledge and
experience with respect to the biotechnology,
healthcare and pharmaceutical industries,
comprehensive leadership background resulting from
service as an executive in the biotechnology industry,
and his ability to bring historic knowledge and
continuity to the Board.
Committee Assignments:
•None
Other Current Public Company Boards:
•Vera Therapeutics, Inc. (Chair), serving on the
Audit Committee and the Nominating and
Corporate Governance Committee
|
Michael M. Morrissey, Ph.D., has served as a director and as Exelixis' President and
Chief Executive Officer since July 2010. Dr. Morrissey has held positions of increasing
responsibility at Exelixis since he joined the company in February 2000, including
serving as President of Research and Development from January 2007 to July 2010.
From 1991 to 2000, Dr. Morrissey held several positions at Berlex Biosciences, last
holding the position of Vice President, Discovery Research. Earlier in his career,
Dr. Morrissey served as a Senior Scientist and Project Team Leader in Medicinal
Chemistry at CIBA-Geigy Corporation. Dr. Morrissey has served as Chair of the board of
directors of Vera Therapeutics, Inc., a publicly held, clinical-stage biotechnology
company focused on developing and commercializing transformative treatments for
patients with serious immunological diseases, since April 2022, and previously served
as a member of the board of directors of XWPharma Ltd., a privately held,
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel therapeutics, from December 2020 to April 2023, and as a
member of the board of directors of CERo Therapeutics, Inc., a privately held
biopharmaceutical company focused on next-generation cell-based therapies for
cancer, from January 2022 to November 2022. He is the author of numerous scientific
publications in medicinal chemistry and drug discovery and an inventor on 70 issued
U.S. patents and 25 additional published U.S. patent applications. Dr. Morrissey holds
a B.S. (Honors) in Chemistry from the University of Wisconsin and a Ph.D. in Chemistry
from Harvard University.
|
|
Robert (Bob) L. Oliver, Jr.
Executive Advisor
|
Director 2023
Age 65
Key Qualifications and Expertise:
Our Board concluded that Mr. Oliver should continue
to serve as a director of Exelixis due to his leadership
experience and expertise in the field of
pharmaceutical commercialization, his memberships
on the boards of directors of various pharmaceutical
and biotechnology companies and his extensive
experience in financial strategy and business
development.
Committee Assignments:
•Compensation Committee
•Risk Committee
Other Current Public Company Boards:
•PsyBio Therapeutics Corp.
|
Robert L. Oliver, Jr. has been a director since May 2023. From 2010 to 2020, Mr. Oliver
served in a variety of senior positions at Otsuka America Pharmaceutical, Inc., a
pharmaceutical company and subsidiary of Otsuka Holdings Co. Ltd., including
President and Chief Executive Officer from 2016 to 2017, President and Chief
Operating Officer from 2014 to 2016, Vice President of Sales and Marketing from 2010
to 2014, and as Chairman of Otsuka Canada Pharmaceutical, Inc. from 2016 to 2020.
Prior to joining Otsuka, he served in a variety of senior positions at Wyeth
Pharmaceuticals, a pharmaceutical company, where he also served as Senior Vice
President from 2008 to 2010 and Vice President from 2005 to 2008. Mr. Oliver began
his career with Johnson & Johnson, a pharmaceutical and consumer packaged goods
company, where he held a variety of positions from 1989 to 2005. In addition,
Mr. Oliver has served as an Executive Advisor of CELLIX Biosciences, a
biopharmaceutical company, since 2018, and Hyalo Technologies, LLC, since 2017.
Mr. Oliver has served as a member of the board of directors of PsyBio Therapeutics
Corp., a publicly held biotechnology company, since 2021, as a member of the board
of directors of Neurotez, Inc., a privately held biotechnology company, since 2017, and
as a member of the board of directors of Hyalo Technologies, LLC, a privately held
biotechnology and biopharmaceutical company, since 2017. Previously, he served as a
member of the board of directors and as Executive Advisor of Medison Canada, an
affiliate of Medison Pharma Ltd., from 2018 to 2022, and as a member of the board of
directors of Immunomedics, Inc., a publicly held biotechnology company, from
January 2017 until its acquisition by Gilead Sciences, Inc. in March 2017. In the not-for-
profit sector, Mr. Oliver serves on the Pharma Board of Advisors at Saint Joseph's
University and on the Board of Governors of the Accreditation Council for Medical
Affairs. Mr. Oliver holds a B.A. from Rutgers University and an M.B.A. from Saint
Joseph's University.
|
|
Table of Contents
|
16
|
Exelixis, Inc.
|
Stelios Papadopoulos, Ph.D.
Co-Founder and Chair of the Board, Exelixis, Inc.
|
Director since 1994
Age 75
Key Qualifications and Expertise:
Our Board concluded that Dr. Papadopoulos should
continue to serve as a director of Exelixis due to his
training as a scientist, his knowledge and experience
with respect to the biotechnology, healthcare and
pharmaceutical industries, his broad leadership
experience resulting from extensive service on various
boards, his knowledge and experience with respect to
finance matters, and his ability to bring historic
knowledge and continuity to the Board.
Committee Assignments:
•Audit Committee
•Compensation Committee
•Research & Development Committee
Other Current Public Company Boards:
•Regulus Therapeutics, Inc. (Chair), serving on
the Audit Committee and the Nominating and
Governance Committee
|
Stelios Papadopoulos, Ph.D., a co-founder of Exelixis, has been a director since
December 1994 and the Chair of the Board since January 1998. Dr. Papadopoulos
retired as Vice Chairman of Cowen & Co., LLC in 2006 after six years as an investment
banker with the firm, where he focused on the biotechnology and pharmaceutical
sectors. Prior to joining Cowen & Co., he spent 13 years as an investment banker at
PaineWebber, Incorporated, where he was most recently Chairman of PaineWebber
Development Corp., a PaineWebber subsidiary focusing on biotechnology. He joined
PaineWebber in 1987 from Drexel Burnham Lambert, where he was a Vice President in
the Equity Research Department covering the biotechnology industry. Prior to Drexel,
he was a biotechnology analyst at Donaldson, Lufkin & Jenrette. Before coming to Wall
Street in 1985, Dr. Papadopoulos was on the faculty of the Department of Cell Biology
at New York University Medical Center. Dr. Papadopoulos was a co-founder of Anadys
Pharmaceuticals, Inc., a publicly held biopharmaceutical company dedicated to
improving patient care by developing novel medicines for the treatment of hepatitis C,
acquired by F. Hoffmann-La Roche Ltd. in 2011. Dr. Papadopoulos served as a member
of the board of directors of Anadys Pharmaceuticals from 2000 to 2011 and as its
Chairman in 2011, prior to its acquisition. Dr. Papadopoulos has served as a member
of the board of directors of Regulus Therapeutics Inc., a publicly held
biopharmaceutical company focused on the development of medicines targeting
microRNAs, since 2008, and as its Chairman since 2013, as a member of the board of
directors of Graviton Bioscience Corporation, a privately held biopharmaceutical
company focused on novel therapeutics designed for the treatment of autoimmune,
cancer, certain genetic, fibrotic, and other serious diseases, since September 2023,
and as co-founder and Chairman of the board of directors of Epikast, Inc., a privately
held company focused on providing sales, medical affairs, market access, patient
engagement and other services to pharmaceutical companies, since June 2023. He
previously served as a member of the board of directors of three other publicly held
companies: Biogen, Inc., a biopharmaceutical company focused on the treatment of
serious diseases, from 2008 to 2023, and as its Chairman from 2014 to 2023; Eucrates
Biomedical Acquisition Corp., a special purpose acquisition company (SPAC) formed
for the purpose of effecting a merger, share exchange, asset acquisition, share
purchase, reorganization or similar business combination with one or more
businesses, and as its Chairman, from 2020 to 2023; and BG Medicine, Inc., a
diagnostics company focused on the development and commercialization of
cardiovascular diagnostic tests, from 2003 until 2018. Dr. Papadopoulos was also co-
founder and member of the board of directors of Cellzome Inc., a privately held drug
discovery company acquired by GSK plc (formerly GlaxoSmithKline) in 2012. In the not-
for-profit sector, Dr. Papadopoulos is a co-founder and Chairman of Fondation Santé,
and until 2023, he served as a member of the board of visitors of Duke Medicine, and
a member of the Global Advisory Board of the Duke Institute for Health Innovation.
Dr. Papadopoulos holds an M.S. in Physics, a Ph.D. in Biophysics and an M.B.A. in
Finance, all from New York University.
|
|
Table of Contents
|
Proposal 1 | Director Nominees
|
2024 Proxy Statement
|
17
|
George Poste, DVM, Ph.D., FRS
Chief Scientist, Complex Adaptive Systems Initiative
|
Director since 2004
Age 79
Key Qualifications and Expertise:
Our Board concluded that Dr. Poste should continue to
serve as a director of Exelixis due to his training as a
scientist, his knowledge and experience with respect
to the life sciences, healthcare and pharmaceutical
industries, his broad leadership experience resulting
from service on various boards, and his knowledge and
experience with policymaking, regulatory issues and
other governmental matters.
Committee Assignments:
•Research & Development Committee (Chair)
•Risk Committee
Other Current Public Company Boards:
•None
|
George Poste, DVM, Ph.D., FRS, has been a director since August 2004. Since 2009,
Dr. Poste has been the Chief Scientist at Complex Adaptive Systems Initiative and
Regents' Professor and Del E. Webb Professor of Health Innovation at Arizona State
University. From 2003 to 2009, Dr. Poste served as the director of the Biodesign
Institute at Arizona State University. Dr. Poste has served as the Chief Executive Officer
of Health Technology Networks, a consulting company that specializes in the
application of genomic technologies and computing in healthcare, since 2000. From
1992 to 1999, he was the Chief Science and Technology Officer and President, R&D, of
SmithKline Beecham Corporation, a pharmaceutical company (later merged into
GlaxoSmithKline plc). Dr. Poste served on the Defense Science Board of the U.S.
Department of Defense from 2001 to 2010 and is a member of other organizations
dedicated to advancing defenses against bioweapons and biowarfare. Dr. Poste has
served as a member of the board of directors of Caris Life Sciences, a privately held
medical diagnostics company, since 2009, and as a member of the board of directors
of MediSix Therapeutics Pte. Ltd. (Singapore), a privately held immune engineering
company developing novel cellular therapies to address Ta cell malignancies, since
2022. Previously, Dr. Poste served as a member of the board of directors of InanoBio,
Inc., a privately held biotechnology company, from 2021 to 2023, as a member of the
board of directors of Monsanto Company, a publicly held provider of agricultural
products and solutions, from 2003 until its acquisition by Bayer Aktiengesellschaft in
2018, and as the Non-executive Chairman of Orchid Cellmark, Inc., a publicly held DNA
forensics company, from 2000 until its acquisition by the Laboratory Corporation of
America in 2009. Dr. Poste is a Fellow of the Royal Society, the UK Academy of Medical
Sciences, Hoover Institution, Stanford University, and various other prestigious
organizations and has been awarded honorary doctorates from several universities.
Dr. Poste holds a DVM in veterinary medicine and a Ph.D. in Virology from the
University of Bristol, England and Board Certification in Pathology from the Royal
College of Pathologists.
|
|
Table of Contents
|
18
|
Exelixis, Inc.
|
Julie Anne Smith
Chief Executive Officer, Nuvig Therapeutics, Inc.
|
Director since 2016
Age 53
Key Qualifications and Expertise:
Our Board concluded that Ms. Smith should continue
to serve as a director of Exelixis due to her knowledge
and experience with respect to biotechnology,
healthcare and pharmaceutical industries and her
broad leadership experience resulting from service as
an executive in the pharmaceutical industry.
Committee Assignments:
•Audit Committee
•Compensation Committee (Chair)
Other Current Public Company Boards:
•Stoke Therapeutics, Inc., serving on the
Compensation Committee
|
Julie Anne Smith has been a director since September 2016. Since January 2023,
Ms. Smith has served as Chief Executive Officer and a member of the board of
directors of Nuvig Therapeutics, Inc., a privately held biopharmaceutical company
developing proprietary recombinant human therapeutics for patients with
autoimmune disease. Previously, Ms. Smith served as President and Chief Executive
Officer and as a member of the board of directors of ESCAPE Bio Inc., a privately held,
clinical-stage biopharmaceutical company developing novel, precisely targeted
therapeutics for genetically defined neurodegenerative diseases, from 2018 to 2022,
and as President and Chief Executive Officer and as a member of the board of
directors of Nuredis, Inc., a privately held biotechnology company, from 2017 to 2018.
Prior to Nuredis, she served as President and Chief Executive Officer of Raptor
Pharmaceutical Corp., a publicly held biopharmaceutical company focused on
developing and commercializing transformative treatments for people affected by rare
and debilitating diseases, from 2015 until the company's acquisition by Horizon
Pharma plc in 2016, where she also served as Executive Vice President and Chief
Operating Officer from 2012 to 2014. From 2008 to 2012, Ms. Smith served as Chief
Commercial Officer of Enobia Pharmaceuticals prior to the company's acquisition by
Alexion Pharmaceuticals, Inc. Previously, Ms. Smith served as Vice President of
Commercial at Jazz Pharmaceuticals plc from 2006 to 2008, as Vice President, Global
Marketing at Genzyme General from 2001 to 2005, and helped to establish the
operations and business development function for the biotech start-up, Novazyme
Pharmaceuticals, from 2000 to 2001. Ms. Smith began her industry career at Bristol-
Myers Squibb Company in 1996. Ms. Smith has served as a member of the board of
directors of Stoke Therapeutics, Inc., a publicly held biotechnology company
pioneering a new way to treat the underlying cause of genetic diseases by precisely
unregulating protein expression, since 2020. Previously, Ms. Smith served as a
member of the board of directors of Audentes Therapeutics, Inc. a publicly held,
clinical-stage biotechnology company focused on developing and commercializing
gene therapy products for patients suffering from serious, life-threatening rare
diseases caused by single gene defects, from 2016 until its acquisition by Astellas
Pharma Inc. in 2020, and as a Director on the Health and Emerging Companies
Sections of the Biotechnology Innovation Organization (BIO) board. Ms. Smith holds a
B.S. in biological and nutritional sciences from Cornell University.
|
|
Jack L. Wyszomierski
Former Executive Vice President and Chief Financial Officer, VWR
International, LLC
|
Director since 2004
Age 68
Key Qualifications and Expertise:
Our Board concluded that Mr. Wyszomierski should
continue to serve as a director of Exelixis due to his
extensive financial reporting, accounting, and finance
experience, as well as his experience in the healthcare
and life sciences industries. These qualities have also
formed the basis for the Board's decision to appoint
Mr. Wyszomierski as a member and Chair of the
Audit Committee.
Committee Assignments:
•Audit Committee (Chair)
•Governance Committee
Other Current Public Company Boards:
•XOMA Corporation (chair), serving on the Audit
Committee and the Compensation Committee
•Athersys, Inc., serving on the Audit Committee,
the Compensation Committee and the
Nominations, Governance and Compliance
Committee (Chair)
•SiteOne Landscape Supply, Inc., serving on the
Audit Committee and the Nominating &
Corporate Governance Committee (Chair)
|
Jack L. Wyszomierski has been a director since February 2004. From 2004 to 2009,
Mr. Wyszomierski served as the Executive Vice President and Chief Financial Officer of
VWR International, LLC, a supplier of laboratory supplies, equipment and supply chain
solutions to the global research laboratory industry. From 1982 to 2003,
Mr. Wyszomierski held positions of increasing responsibility within the finance group
at Schering-Plough Corporation, a health care company, culminating with his
appointment as Executive Vice President and Chief Financial Officer in 1996. Prior to
joining Schering-Plough, he was responsible for capitalization planning at Joy
Manufacturing Company, a producer of mining equipment, and was a management
consultant at Data Resources, Inc. Mr. Wyszomierski has served: as a member of the
board of directors of XOMA Corporation, a publicly held biotech royalty aggregator,
since 2010, and as its Chairman since January 2024; as a member of the board of
directors of Athersys, Inc., a publicly held company engaged in the discovery and
development of therapeutic product candidates, since 2010; and as a member of the
board of directors of SiteOne Landscape Supply, Inc., a publicly held company that
distributes landscape supply products, since 2016. Mr. Wyszomierski previously served
as a member of the board of directors of: Unigene Laboratories, Inc., a publicly held
biopharmaceutical company, from 2010 to 2013; AssuraMed Holding, Inc., a privately
held distributor of home healthcare products, from 2011 until its acquisition by
Cardinal Health Inc. in 2013; and Solenis, Inc., a privately held chemicals producer
from 2014 until its acquisition by Platinum Equity in 2021. Mr. Wyszomierski holds a
M.S. in Industrial Administration and a B.S. in Administration, Management Science
and Economics from Carnegie Mellon University.
|
|
THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" EACH NAMED NOMINEE.
|
Table of Contents
|
Proposal 1 | Director Nominees
|
2024 Proxy Statement
|
19
|
•Evaluating the performance, qualifications,
compensation and continued engagement
of the independent registered public
accounting firm, as well as resolving any
disagreements between the independent
registered public accounting firm
and management
|
•Reviewing the financial statements for
inclusion in our Annual Report on Form 10-K
and preparing the Audit Committee's report
for inclusion in our Proxy Statement or
Annual Report on Form 10-K
|
•Reviewing our tax strategy, material tax
audits and proceedings and any other
material tax matters
|
•Establishing procedures to receive and
address complaints regarding accounting,
internal accounting controls or
auditing matters
|
•Reviewing, overseeing and approving related
person transactions
|
•Reviewing the results of the annual audit
and the quarterly financial statement
reviews with management and the
independent registered public
accounting firm
|
•Overseeing our management of risks
relating to financial reporting, fraud,
securities trading and tax matters
|
•Maintaining compliance with SEC and
Nasdaq rules applicable to audit committees
|
•Serving as the Qualified Legal Compliance
Committee within the meaning of Rule
205.2(k) of Title 17, Chapter II of the Code
of Federal Regulations
|
•Reviewing and approving our decisions to
enter into certain swaps and other
derivatives transactions, as well as our
overall hedging strategy
|
Table of Contents
|
20
|
Exelixis, Inc.
|
•Assessing compensation policies and
practices and reviewing
executive compensation
|
•Evaluating director compensation and
recommending any changes to the Board
for approval
|
•Reviewing our Compensation Discussion
and Analysis and preparing the
Compensation Committee's report for
inclusion in our Proxy Statement
|
•Administering equity awards under our
stock plans
|
•Addressing any conflict of interest
with any compensation adviser
engaged by management or the
Compensation Committee
|
•Assisting the Board in its oversight of our
human capital management function,
including recruiting, retention, career
development and progression, non-CEO
management succession and diversity
|
•Establishing compensation and benefits
policies for employees, including
executive officers
|
•Overseeing annual evaluations of
performance of our executive officers
|
•Establishing, overseeing and reviewing
stock ownership guidelines for directors
and executive officers
|
Table of Contents
|
Proposal 1 |Board Committees
|
2024 Proxy Statement
|
21
|
•Overseeing our governance practices,
including recommending to the Board for
approval of any changes to our corporate
governance framework
|
•Identifying, evaluating and recommending
qualified director candidates to the Board
|
•Ensuring effective communication between
the Board, its committees and
management, as well as establishing
procedures for stockholders'
communications to the Board
|
•Developing Corporate Governance
Guidelines and administering our Corporate
Code of Conduct
|
•Conducting periodic assessments of the
performance of the Board and its
committees and compliance with SEC and
Nasdaq requirements for independence
and expertise
|
•Conducting periodic assessments of
sustainability strategy and policies (including
ESG matters), and overseeing management
in their implementation and the preparation
of public disclosures pertaining to ESG
programs and sustainability efforts
|
•Facilitating CEO succession planning
|
•Overseeing the orientation program for
new directors and continuing education of
all directors
|
Table of Contents
|
22
|
Exelixis, Inc.
|
•Overseeing our clinical development
program and internal drug
discovery activities
|
•Reviewing the overall organization,
resourcing and capabilities of our research
and development business units
|
•Reviewing the progress of preclinical and
clinical assets that we have in-licensed or
acquired and evaluating the scientific
aspects of potential future business
development opportunities
|
•Evaluating and discussing trends in the
oncology treatment landscape and potential
effects on our pipeline strategy and other
business needs
|
•Advising the Board on other matters of
scientific importance as the Board, in
consultation with management, may
designate from time to time
|
Table of Contents
|
Proposal 1 |Board Committees
|
2024 Proxy Statement
|
23
|
•Reviewing our overall risk management
framework and infrastructure designed to
identify, assess, manage and mitigate our
material risks
|
•Overseeing management's administration of
government and other investigations and
material litigation matters
|
•Overseeing management's administration
of our various compliance programs,
including, but not limited to, those relating
to data privacy and cybersecurity, drug
safety, healthcare compliance and quality
management
|
•Overseeing management's identification,
assessment and management of our
business and operational risks not
specifically allocated to the Board or another
committee of the Board, and obtaining
periodic reports from our Ethics Committee
|
•Reviewing the policies, guidelines and
practices for managing business and
operational risks
|
•Evaluating trends in risk management and
advising the Board on best practices with
respect to risk management strategy
and implementation
|
Board of
Directors
|
Audit
Committee
|
Compensation
Committee
|
Nominating
and Corporate
Governance
Committee
|
Research &
Development
Committee
|
Risk
Committee
|
|
Number of Meetings Held in
Fiscal 2023
|
8
|
4
|
8
|
3
|
2
|
2
|
Table of Contents
|
24
|
Exelixis, Inc.
|
Table of Contents
|
Proposal 1 |Corporate Governance
|
2024 Proxy Statement
|
25
|
Table of Contents
|
26
|
Exelixis, Inc.
|
Table of Contents
|
Proposal 1 |Corporate Governance
|
2024 Proxy Statement
|
27
|
Table of Contents
|
28
|
Exelixis, Inc.
|
Table of Contents
|
Proposal 1 |Corporate Governance
|
2024 Proxy Statement
|
29
|
Table of Contents
|
30
|
Exelixis, Inc.
|
Table of Contents
|
Compensation of Directors
|
2024 Proxy Statement
|
31
|
Annual Cash
Compensation ($)
|
|||
Service
|
Fee Type
|
Q1 - Q3 2023
|
Q4 2023
|
Board
|
Retainer Fee
|
55,000
|
60,000
|
Additional Chair Retainer Fee
|
31,000
|
35,000
|
|
Meeting Fee (1)(2)
|
2,500
|
N/A
|
|
Audit Committee
|
Retainer Fee
|
12,000
|
15,000
|
Additional Chair Retainer Fee
|
13,000
|
15,000
|
|
Meeting Fee (1)(3)
|
1,000
|
N/A
|
|
Compensation Committee
|
Retainer Fee
|
10,000
|
12,000
|
Additional Chair Retainer Fee
|
10,000
|
13,000
|
|
Meeting Fee (1)(3)
|
1,000
|
N/A
|
|
Nominating & Corporate Governance Committee
|
Retainer Fee
|
5,000
|
12,000
|
Additional Chair Retainer Fee
|
10,000
|
13,000
|
|
Meeting Fee (1)(4)
|
1,000
|
N/A
|
|
Research & Development Committee
|
Retainer Fee
|
5,000
|
12,000
|
Additional Chair Retainer Fee
|
10,000
|
13,000
|
|
Meeting Fee (1)(4)
|
1,000
|
N/A
|
|
Risk Committee
|
Retainer Fee
|
5,000
|
12,000
|
Additional Chair Retainer Fee
|
10,000
|
13,000
|
|
Meeting Fee (1)(4)
|
1,000
|
N/A
|
Table of Contents
|
32
|
Exelixis, Inc.
|
Table of Contents
|
Compensation of Directors
|
2024 Proxy Statement
|
33
|
Fees Earned or
Paid in Cash
($)
|
Stock Awards
($)(1)
|
Option Awards
($)(2)
|
All Other
Compensation
($)(3)
|
Total
($)
|
|
Carl B. Feldbaum, Esq. (4)
|
37,500
|
-
|
-
|
50,000
|
87,500
|
Maria C. Freire, Ph.D.
|
87,000
|
401,722
|
-
|
488,722
|
|
Alan M. Garber, M.D., Ph.D. (5)
|
80,500
|
-
|
400,667
|
481,167
|
|
Tomas J. Heyman (6)
|
37,250
|
350,433
|
328,508
|
716,191
|
|
David E. Johnson (6)
|
39,750
|
350,433
|
328,508
|
718,691
|
|
Vincent T. Marchesi, M.D., Ph.D. (4)
|
35,000
|
-
|
-
|
50,000
|
85,000
|
Robert L. Oliver, Jr. (6)
|
38,500
|
350,433
|
328,508
|
717,441
|
|
Stelios Papadopoulos, Ph.D.
|
118,250
|
401,722
|
-
|
519,972
|
|
George Poste, DVM, Ph.D., FRS
|
80,500
|
401,722
|
-
|
482,222
|
|
Julie A. Smith
|
90,250
|
-
|
400,667
|
490,917
|
|
Lance Willsey, M.D. (7)
|
35,000
|
-
|
-
|
35,000
|
|
Jacqueline Wright (5)
|
69,750
|
401,722
|
-
|
471,472
|
|
Jack L. Wyszomierski
|
89,250
|
401,722
|
-
|
490,972
|
Table of Contents
|
34
|
Exelixis, Inc.
|
Table of Contents
|
Compensation of Directors |Director Compensation Table
|
2024 Proxy Statement
|
35
|
THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" PROPOSAL 2.
|
Table of Contents
|
36
|
Exelixis, Inc.
|
Fiscal Year Ended
|
||
December 29,
2023
|
December 30,
2022
|
|
Audit fees (1)
|
$2,805,390
|
$2,611,000
|
Audit-related fees (2)
|
130,000
|
275,000
|
Tax fees:
|
547,405
|
481,560
|
Tax compliance fees (3)
|
259,100
|
246,735
|
Other tax fees (4)
|
288,305
|
234,825
|
All other fees (5)
|
-
|
2,000
|
Total Fees
|
$3,482,795
|
$3,369,560
|
Table of Contents
|
Proposal 2 | Ratification of Selection of Independent Registered Public Accounting Firm
|
2024 Proxy Statement
|
37
|
Table of Contents
|
38
|
Exelixis, Inc.
|
Table of Contents
|
Proposal 3 | Amendment and Restatement of the Exelixis, Inc. 2000 Employee Stock Purchase Plan
|
2024 Proxy Statement
|
39
|
Table of Contents
|
40
|
Exelixis, Inc.
|
Table of Contents
|
Proposal 3 | Amendment and Restatement of the Exelixis, Inc. 2000 Employee Stock Purchase Plan
|
2024 Proxy Statement
|
41
|
Table of Contents
|
42
|
Exelixis, Inc.
|
Table of Contents
|
Proposal 3 | Amendment and Restatement of the Exelixis, Inc. 2000 Employee Stock Purchase Plan
|
2024 Proxy Statement
|
43
|
Name and position
|
Number of
shares
|
Michael M. Morrissey, Ph.D.
President and Chief Executive Officer
|
2,056
|
Christopher J. Senner
Executive Vice President and Chief Financial Officer
|
10,464
|
Dana T. Aftab
Executive Vice President, Discovery and Translational Research and Chief Scientific Officer
|
73,752
|
Jeffrey J. Hessekiel, J.D.
Executive Vice President, General Counsel and Secretary
|
8,924
|
Amy C. Peterson, M.D.
Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer
|
-
|
Vicki L. Goodman, M.D.
Former Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer
|
-
|
All current executive officers as a group
|
149,063
|
All current directors who are not executive officers as a group
|
-
|
All employees, including all current officers who are not executive officers, as a group
|
11,080,519
|
Table of Contents
|
44
|
Exelixis, Inc.
|
Plan Category
|
Number of securities
to be issued upon
exercise of
outstanding
options, warrants
and
rights (a)
|
Weighted-
average
exercise price of
outstanding
options,
warrants and
rights (b)
|
Number of securities
remaining
available for future
issuance
under equity compensation
plans (excluding securities
reflected in column (a)) (c)
|
Equity compensation plans approved
by stockholders
|
23,898
|
$7.23
|
29,581
|
Equity compensation plans not approved
by stockholders
|
75
|
$20.61
|
-
|
Total
|
23,973
|
$7.27
|
29,581
|
THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" PROPOSAL 3.
|
Table of Contents
|
Proposal 3 | Amendment and Restatement of the Exelixis, Inc. 2000 Employee Stock Purchase Plan
|
2024 Proxy Statement
|
45
|
THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" PROPOSAL 4.
|
Table of Contents
|
46
|
Exelixis, Inc.
|
Beneficially Owned (1)
|
||
Name of Beneficial Owner
|
Number of
Shares of
Common Stock
|
Percentage
of Total
|
Named Executive Officers and Directors
|
||
Michael M. Morrissey, Ph.D. (2)
|
2,685,808
|
*
|
Christopher J. Senner (3)
|
679,766
|
*
|
Dana T. Aftab, Ph.D. (4)
|
406,671
|
*
|
Jeffrey J. Hessekiel, J.D. (5)
|
598,161
|
*
|
Amy C. Peterson, M.D. (6)
|
-
|
*
|
Vicki L. Goodman, M.D. (7)
|
61,271
|
*
|
Mary C. Beckerle, Ph.D. (8)
|
30,848
|
*
|
S. Gail Eckhardt, M.D. (9)
|
30,848
|
*
|
Maria C. Freire, Ph.D. (10)
|
156,503
|
*
|
Alan M. Garber, M.D., Ph.D. (11)
|
279,524
|
*
|
Tomas J. Heyman (12)
|
36,353
|
*
|
David E. Johnson (13)
|
1,137,083
|
*
|
Robert L. Oliver, Jr. (14)
|
36,353
|
*
|
Stelios Papadopoulos, Ph.D. (15)
|
1,287,805
|
*
|
George Poste, DVM, Ph.D., FRS (16)
|
241,383
|
*
|
Julie A. Smith (17)
|
216,533
|
*
|
Jacqueline Wright (18)
|
82,685
|
*
|
Jack L. Wyszomierski (19)
|
397,715
|
*
|
All current directors and executive officers as a group (18 persons) (20)
|
8,638,652
|
2.85%
|
5% Stockholders
|
||
BlackRock, Inc. (21)
55 East 52ndStreet
New York, New York 10055
|
36,013,885
|
12.0%
|
The Vanguard Group (22)
100 Vanguard Blvd.
Malvern, Pennsylvania 19355
|
31,671,090
|
10.6%
|
Farallon Capital Partners, L.P. (23)
One Maritime Plaza
San Francisco, California 94111
|
25,860,000
|
8.6%
|
Renaissance Technologies LLC (24)
800 Third Avenue
New York, New York 10022
|
15,615,716
|
5.2%
|
Table of Contents
|
Security Ownership of Certain Beneficial Owners and Management
|
2024 Proxy Statement
|
47
|
Table of Contents
|
48
|
Exelixis, Inc.
|
Table of Contents
|
Security Ownership of Certain Beneficial Owners and Management
|
2024 Proxy Statement
|
49
|
Name
|
Age
|
Position
|
Michael M. Morrissey, Ph.D. (1)
|
63
|
President and Chief Executive Officer
|
Christopher J. Senner
|
56
|
Executive Vice President and Chief Financial Officer
|
Dana T. Aftab, Ph.D.
|
61
|
Executive Vice President, Discovery and Translational Research and Chief
Scientific Officer
|
Patrick J. Haley
|
48
|
Executive Vice President, Commercial
|
Jeffrey J. Hessekiel, J.D.
|
55
|
Executive Vice President, General Counsel and Secretary
|
Amy C. Peterson, M.D.
|
57
|
Executive Vice President, Product Development and Medical Affairs and
Chief Medical Officer
|
Christopher J. Senner
Executive Vice President and Chief Financial Officer
|
Christopher J. Senner, has served as Executive Vice President and Chief Financial Officer (and in such capacity, as our
principal financial officer and principal accounting officer, as defined under applicable securities laws) since July 2015.
Prior to joining Exelixis, Mr. Senner served as Vice President, Corporate Finance for Gilead Sciences, Inc., a
biopharmaceutical company, from March 2010 to July 2015, where he was accountable for controllership, tax,
treasury and corporate and operational financial planning. Mr. Senner previously spent eighteen years at Wyeth, a
pharmaceutical company acquired by Pfizer Inc. in 2009, in a variety of financial roles with increasing responsibility,
most notably as Chief Financial Officer of Wyeth's U.S. pharmaceuticals business and the BioPharma Business Unit.
Since 2019, Mr. Senner has served as a member of the board of directors of Quince Therapeutics, Inc. (f/k/a
Cortexyme, Inc.), a publicly held clinical-stage biopharmaceutical company. Mr. Senner holds a B.S. in Finance from
Bentley College.
|
Dana T. Aftab, Ph.D.
Executive Vice President, Discovery and Translational Research and Chief Scientific Officer
|
Dana T. Aftab, Ph.D., has served as Executive Vice President, Discovery and Translational Research and Chief Scientific
Officer at Exelixis since December 2022. Previously, he served as Executive Vice President, Business Operations from
February 2016 to December 2022, during which time he oversaw the company's corporate site development and
campus operations, including the opening of new laboratory buildings at Exelixis' Alameda campus and the ongoing
buildout of the company's Exelixis East footprint in the Greater Philadelphia area. Dr. Aftab first joined Exelixis in
1998, starting in Exelixis' Drug Discovery organization, where he led teams that drove the discovery and development
of the company's approved medicines, including cabozantinib. In 2007, he moved into the company's clinical
development organization, where he led the effort to streamline Exelixis' processes for transitioning drug discovery
programs into clinical development, serving as Senior Vice President, Translational Research from 2009 to 2016. Prior
to joining Exelixis, Dr. Aftab held senior scientist positions at several biotech start-ups. Dr. Aftab holds B.A. and Ph.D.
degrees in pharmacology from the University of California, Santa Barbara and Yale University, respectively, and did his
postdoctoral work at the University of California, Berkeley in the field of oncogene signaling.
|
Table of Contents
|
50
|
Exelixis, Inc.
|
Patrick J. Haley
Executive Vice President, Commercial
|
Patrick J. Haley, has served as the company's Executive Vice President, Commercial since February 2020 and has held
positions of progressive commercial leadership since September 2010, serving as Senior Vice President, Commercial
from December 2016 to February 2020, Vice President, Commercial from November 2014 to November 2016,
Executive Director, Sales & Marketing from September 2013 to October 2014, Senior Director, Marketing from March
2012 to August 2013, and as Director, Marketing from September 2010 to February 2012. Prior to joining Exelixis,
from 2007 to 2010, he held positions of increasing responsibility at Genentech, Inc., on the Avastin marketing team,
most recently Group Product Manager. Between 2003 and 2007, Mr. Haley served in various sales and marketing
roles at Amgen, Inc. He served as an analyst at PWC Securities, Lehman Brothers and Accenture from 1998 to 2001.
Mr. Haley holds a Masters of Business Administration from University of Michigan, Ross School of Business, and a
Bachelor of Arts in Art History and Medieval and Renaissance Studies from Duke University.
|
Jeffrey J. Hessekiel, J.D.
Executive Vice President, General Counsel and Secretary
|
Jeffrey J. Hessekiel, J.D., has served as Executive Vice President and General Counsel since February 2014, and as
Secretary from October 2014 to September 2017, before resuming in January 2022. From 2012 to 2014, he held the
position of Senior Counsel at Arnold & Porter Kaye Scholer LLP, where he advised emerging growth and public
companies, primarily in the life sciences sector, on complex legal issues connected with strategic transactions,
healthcare compliance programs and investigations, and regulatory matters. Prior to working with Arnold & Porter,
from 2002 to 2012, he held positions of increasing responsibility at Gilead Sciences, Inc., most recently as Chief
Compliance & Quality Officer where he was responsible for the creation and management of Gilead's Corporate
Compliance & Quality department. From 1998 to 2002, Mr. Hessekiel held the position of Associate, working on both
litigation and corporate matters for Wilson Sonsini Goodrich and Rosati PC. Mr. Hessekiel also worked as an
Associate focusing on litigation matters for Heller Ehrman LLP from 1996 to 1998. Prior to joining Heller Ehrman LLP,
Mr. Hessekiel also worked for several international non-governmental organizations. Mr. Hessekiel received his J.D.
from The George Washington University Law School and is admitted to practice in California. Mr. Hessekiel received a
B.A. in Political Science from Duke University.
|
Amy C. Peterson, M.D.
Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer
|
Amy Peterson, M.D., has served as Executive Vice President, Product Development and Medical Affairs and Chief
Medical Officer at Exelixis since August 2023. Dr. Peterson is an oncologist and veteran drug development leader
with nearly two decades of experience advancing therapies for people with cancer. Prior to joining Exelixis, from
October 2019 to September 2022, she served as Executive Vice President and Chief Development Officer and then as
President and Chief Operating Officer at CytomX Therapeutics, Inc. Previously, from August 2016 to February 2019,
Dr. Peterson served as Chief Medical Officer of Immuno-oncology at BeiGene, Inc., where she built the company's
development organization with oversight of all assets in solid tumor indications, including the checkpoint inhibitor
tislelizumab. Prior to BeiGene, from August 2011 to July 2016, she was Vice President of Clinical Development at
Medivation, Inc., where she contributed to the development of enzalutamide (XTANDI®) in prostate cancer and led
breast cancer development for both enzalutamide and talazoparib (TALZENNA®). Dr. Peterson began her industry
career at Genentech, Inc., where, from September 2005 to August 2011, she oversaw the development of early-stage
molecules targeting multiple major pathways in oncology, and worked on many approved agents including
bevacizumab (AVASTIN®), atezolizumab (TECENTRIQ®) and cobimetinib (COTELLIC®). In the not-for-profit sector, she
serves as the Secretary of the Board of Directors of Conquer Cancer Foundation. Dr. Peterson received her M.D. from
Thomas Jefferson University before completing a residency in internal medicine at Northwestern Memorial Hospital
and a fellowship in hematology/oncology at the University of Chicago.
|
Table of Contents
|
Information about our Executive Officers
|
2024 Proxy Statement
|
51
|
Our 2023 NEOs
|
Title
|
Michael M. Morrissey, Ph.D.
|
President and Chief Executive Officer
|
Christopher J. Senner
|
Executive Vice President and Chief Financial Officer
|
Dana T. Aftab, Ph.D.
|
Executive Vice President, Discovery and Translational Research and Chief
Scientific Officer
|
Jeffrey J. Hessekiel, J.D.
|
Executive Vice President, General Counsel and Secretary
|
Amy C. Peterson, M.D. (1)
|
Executive Vice President, Product Development and Medical Affairs and Chief
Medical Officer
|
Vicki L. Goodman, M.D. (2)
|
Former Executive Vice President, Product Development and Medical Affairs and
Chief Medical Officer
|
Table of Contents
|
52
|
Exelixis, Inc.
|
We made significant progress with our product pipeline in 2023 and delivered strong financial results, bolstered by
the performance and continued growth of the cabozantinib franchise as a leading therapy for forms of renal, liver
and thyroid cancer.
|
2023 Financial and Commercial Highlights
|
||
$1.8 billion
Total Revenues, representing 14%
growth year-over-year
|
7
Full years of operating profit
|
39%
CABOMETYX continued to have leading
market position among tyrosine kinase
inhibitors, with a total prescriptions (TRx)
market share of 39% at the end of 2023
|
Returned capital to our stockholders through completion of $550 million share
repurchase program
Announced new $450 million share repurchase program for 2024 to continue returning capital to our stockholders
|
Table of Contents
|
Compensation of Executive Officers | Compensation Discussion and Analysis
|
2024 Proxy Statement
|
53
|
Key Business Performance Highlights
Delivering on strategic objectives
|
|
2
Positive top-line
results (TLR) in
cabozantinib pivotal
trials
|
›› CONTACT-02:Announced in August 2023, CONTACT-02 met one of two primary endpoints,
demonstrating a statistically significant and clinically meaningful improvement in progression-
free survival (PFS) in patients with metastatic castration-resistant prostate cancer and soft-
tissue disease who have progressed after treatment with one prior novel hormonal therapy.
The phase 3 trial continues to the next planned overall survival analysis, anticipated in 2024,
and we are discussing a potential regulatory submission with the FDA this year. If approved,
we believe the combination would represent a compelling and novel option for patients with
a poor prognosis and high unmet need.
›› CABINET:In October 2023, we presented detailed results that demonstrated cabozantinib
provided dramatic improvements in PFS in two cohorts of patients with previously treated
neuroendocrine tumors: one cohort of patients with advanced pancreatic neuroendocrine
tumors (pNET) and a second cohort of patients with advanced extra-pancreatic NET (epNET).
We are discussing these results with the FDA for a potential regulatory submission in 2024.
If approved, we believe that cabozantinib would represent a new treatment option for
patients with previously treated pNET or epNET.
|
2
New clinical trials
evaluating
zanzalintinib:
STELLAR-305 and
STELLAR-009
|
We made substantial progress expanding the clinical development of zanzalintinib, a novel,
potent, third-generation oral tyrosine kinase inhibitors (TKI) that targets VEGF receptors, MET
and the TAM kinases (TYRO3, AXL and MER) implicated in cancer's growth and spread.
›› STELLAR-305: a phase 2/3 pivotal trial will evaluate zanzalintinib in combination with
pembrolizumab, an immune checkpoint inhibitor developed by Merck & Co., Inc., versus
monotherapy pembrolizumab in patients with previously untreated PD-L1-positive recurrent
or metastatic squamous cell cancers of the head and neck (SCCHN)
›› STELLAR-009: an open-label phase 1b/2 trial evaluating zanzalintinib in combination with
AB521, an inhibitor of the transcription factor HIF-2α developed by Arcus Biosciences, Inc., in
patients with advanced solid tumors, including clear cell RCC
|
2
New pipeline clinical
trial programs:
ADU-1805 and XL309
|
››In February 2023, the FDA cleared the initial investigational new drug application (IND) for
ADU-1805, a clinical-stage and potentially best-in-class monoclonal antibody that targets
SIRPα. ADU-1805 is currently being evaluated in a phase 1 clinical trial to explore its
pharmacokinetics, safety, tolerability and preliminary anti-tumor activity in patients with
advanced solid tumors.
›› In September 2023, we acquired global rights to develop and commercialize XL309, a
potentially best-in-class small molecule inhibitor of USP1. We are advancing the phase 1
development of XL309 as a potential therapy for tumors that have become refractory to PARP
inhibitor (PARPi) therapy, including forms of ovarian, breast and prostate cancers, and will
pursue potential PARPi combinations.
|
6
Development
candidates (DCs)
advancing towards IND
submissions in 2024
through 2026
|
During 2023, we advanced multiple DCs toward potential IND filings in 2024 - 2026:
›› XB010, our first ADC advanced internally that targets the tumor antigen 5T4
›› XB628, a bispecific antibody that targets PD-L1 and natural killer cell receptor group 2A
›› XL495, a small molecule inhibitor of protein kinase membrane associated tyrosine/
threonine 1
›› XB371, a next-generation tissue factor-targeting ADC that is differentiated from XB002 by its
topoisomerase inhibitor payload
›› XB064, a high-affinity monoclonal antibody targeting immunoglobin-like transcript 2, which is
associated with resistance to PD-1 pathway inhibitors
›› XB033, an ADC targeting the tumor antigen IL13Rα2
|
Table of Contents
|
54
|
Exelixis, Inc.
|
Key Compensation Actions
|
Description
|
Approved Salary Increases for NEOs
|
In February 2023, the Compensation Committee increased base salaries
for our NEOs (other than Dr. Peterson) by between 3.5% and 4.0% over
salaries of 2022.
|
Approved Annual Cash Bonuses That
Are Aligned with Company Performance
|
In February 2024, the Compensation Committee approved annual cash
bonus payments in amounts between 80% and 101% of each NEO's
2023 target cash bonus amount. These decisions reflect the
Compensation Committee's assessment of the overall achievement of
our pre-determined 2023 corporate goals, and the individual
contributions of each NEO (other than Dr. Morrissey) toward the
achievement of our corporate goals.
|
Granted Performance-Based and
Time-Based Awards under Our Long-
Term Incentive Program (LTIP)
|
In February 2023, the Compensation Committee approved
equity awards for each NEO (other than Dr. Peterson) comprising
approximately 50% performance-based RSU awards (PSUs) and 50%
time-based RSU awards. The Compensation Committee believes this
allocation between PSUs and RSUs provides an effective balance
between retention and performance, risk and leverage, as well as
alignment with the interests of stockholders and creating
long-term value.
|
Did Not Adjust Performance Targets for
LTIP or Annual Cash Bonus Plan
|
The Compensation Committee believes that the performance targets
reflect critical business objectives for the company and that the
programs as originally established remained appropriate. Consequently,
the Compensation Committee did not adjust the performance targets
for awards issued under our LTIP or our Annual Cash Bonus Plan in 2023.
|
Table of Contents
|
Compensation of Executive Officers | Compensation Discussion and Analysis
|
2024 Proxy Statement
|
55
|
Pay for Performance
|
›› NEO compensation is closely linked to our corporate performance
|
Stockholder Alignment
|
›› Long-term equity incentives align the long-term financial interests of
our NEOs with those of our stockholders
|
Compensation Governance
|
›› Our Compensation Committee is made up entirely of independent
directors and engages an independent compensation consultant to
advise on executive compensation matters
|
Stockholder Feedback
|
›› We value and regularly solicit stockholder feedback, including
through an annual stockholder advisory vote to approve our
executive compensation program (referred to herein as Say on Pay)
|
Recoupment or Clawback Policy
|
›› We maintain a Policy for Recoupment of Variable Compensation
(referred to herein as the Clawback Policy) that permits the company
to recoup variable compensation from senior level employees,
including our NEOs, in the event of misconduct that causes material
harm to the company
›› NEW: In September 2023, we amended and restated our Clawback
Policy in accordance with the Dodd-Frank Wall Street Reform and
Consumer Protection Act to provide for recovery of incentive-based
compensation erroneously received by current or former
executive officers, including our NEOs, following a restatement of
financial results
|
Annual Cash Bonus Amounts Subject
to Payment Maximums
|
›› Our Annual Cash Bonus Plan sets a cap of 200% on the payouts of
target bonus payments for individual and/or corporate performance
|
Equity Plan Features
|
›› The 2017 Plan includes minimum vesting requirements of no less
than one year for all types of awards, subject to limited exceptions
›› Applies a maximum 7-year term for stock options
›› Prohibits repricing of underwater stock options without prior
stockholder approval
|
Stock Ownership Guidelines
|
›› We apply, monitor and enforce stock ownership guidelines to
directors and executive officers to further align their interests with
those of our stockholders
›› NEW: In September 2023, we amended our stock ownership
guidelines to increase the target value for the Chief Executive Officer
to 6 times his annual base salary
|
Change in Control Provisions
|
›› Does not include excessive change in control or severance payments
›› Provides "double-trigger" change in control benefits
›› Does not include Code Section 280G tax gross-ups on severance or
change in control benefits
|
Perquisites, Retirement and
Pension Benefits
|
›› Our NEOs do not receive excessive perquisites or post-termination
retirement or pension benefits that are not available to all
employees generally
|
Prohibition on Hedging and
Margin Loans
|
›› We prohibit hedging and purchases on margin by executive officers
and directors
|
Meaningful Limits on Pledging
|
›› We limit pledging of our common stock by executive officers and
directors to circumstances where the individual can clearly
demonstrate the financial capacity to repay the loan without
resorting to the pledged securities
›› No executive officers or directors pledged our common stock
during 2023
|
Compensation Risk Assessment
|
›› Our Compensation Committee annually assesses the risks associated
with our compensation policies and practices to ensure that our
programs are not reasonably likely to have a material adverse effect
on the company
|
Table of Contents
|
56
|
Exelixis, Inc.
|
Table of Contents
|
Compensation of Executive Officers | Compensation Discussion and Analysis
|
2024 Proxy Statement
|
57
|
Range of Governance and Business Topics Discussed with Stockholders During 2023
|
››Board Independence, Composition, Tenure and Refreshment
|
››Business Performance and Corporate Strategy
|
››ESG Disclosures
|
››DEI
|
››Executive Compensation
|
››Human Capital Management
|
Table of Contents
|
58
|
Exelixis, Inc.
|
Our Fiscal 2023 Peers (1)
|
||
ACADIA Pharmaceuticals Inc.
|
Exact Sciences Corporation
|
Neurocrine Biosciences, Inc.
|
Alkermes plc
|
Horizon Therapeutics plc
|
NovoCure Limited
|
Alnylam Pharmaceuticals, Inc.
|
Incyte Corporation
|
Sarepta Therapeutics, Inc.
|
BeiGene, Ltd.
|
Ionis Pharmaceuticals, Inc.
|
Seagen Inc.
|
BioMarin Pharmaceutical Inc.
|
Jazz Pharmaceuticals plc
|
Ultragenyx Pharmaceutical Inc.
|
Blueprint Medicines Corporation
|
Natera, Inc.
|
United Therapeutics Corporation
|
Revenues
|
Market Capitalization
|
Table of Contents
|
Compensation of Executive Officers | Compensation Discussion and Analysis
|
2024 Proxy Statement
|
59
|
0
|
25th
|
50th
|
75th
|
100th
|
Element
|
Description
|
Objective(s)
|
|
Annual Base Salary
|
Annual fixed cash compensation
|
Provide a predictable level of income
that is competitive with our Peers
|
|
Annual Cash Bonus
|
Variable cash compensation based on
corporate performance, including
achievement against pre-determined
corporate goals and the individual
contributions of each NEO toward the
achievement of such corporate goals
|
Align our executive compensation with
our annual corporate goals
Motivate and reward achievement of
corporate goals and overall company
performance, including through
individual contributions
|
|
Long-Term
Incentive
Compensation
|
RSUs (or PSUs,
if performance-
based)
|
Variable share-based compensation,
subject to either time-based yearly
vesting over four years or
performance-based vesting based
on the achievement of key
corporate goals
PSUs generally have a three-year
performance period, with 50% of the
earned PSUs vesting upon the
Compensation Committee's
certification, and the remaining 50%
vesting on the first quarterly vesting
date following the one-year
anniversary of the Compensation
Committee's certification
|
Align the interests of our executives
with those of our stockholders
Motivate our executives to
achieve long-term corporate
performance objectives
Promote retention, including during
periods of stock price volatility
common to biotechnology companies
|
Stock Options
|
Variable share-based compensation
with value derived from appreciation
in our company's stock price
|
Align the interests of our executives
with those of our stockholders
Motivate our executives to achieve
critical business objectives as stock
options only have value if the value of
our company as reflected by our stock
price increases over time
|
Table of Contents
|
60
|
Exelixis, Inc.
|
Element
|
Description
|
401(k) Plan
|
All employees, including NEOs, may contribute their own funds, as salary
deductions, on a pre-tax or after-tax basis, subject to plan and
government limits. For 2023, we matched pre-tax and Roth 401(k)
contributions dollar-for-dollar up to $11,000.
|
Employee Stock Purchase Plan
|
Our ESPP allows all employees, including NEOs, to purchase shares of our
common stock at a price equal to the lower of 85% of the closing price
on the first day of the six-month offering period or 85% of the closing
price on the final day of such offering period, subject to specified limits.
This year, we are requesting stockholder support for our proposal to
increase the number of shares available under our ESPP so that we may
continue to offer this valuable program to our employees.
|
Health Care, Dental and Vision Benefits
|
Subject to applicable laws, these health and welfare benefits are
available to all eligible employees, including NEOs.
|
CIC Plan (1)
|
Participants receive certain plan benefits only if terminated without
cause or constructively terminated, whether or not in connection with a
change-in-control event.
In the context of a change in control, our plan requires a "double-trigger"
- participants are protected in the event of a termination without cause
or constructive termination in connection with a change-in-control
event, but they are encouraged to stay throughout a transition period in
the event of a change in control, and the CIC Plan does not provide for
benefits for a participant who remains with the surviving company in a
comparable position.
To serve our best interests, the plan requires a release of claims against
us as a condition to receiving any severance benefits.
|
Table of Contents
|
Compensation of Executive Officers | Compensation Discussion and Analysis
|
2024 Proxy Statement
|
61
|
Name
|
2022 Base
Salary
|
2023 Base
Salary
|
Percentage
Increase
|
Michael M. Morrissey, Ph.D.
|
$1,155,039
|
$1,201,241
|
4.0%
|
Christopher J. Senner
|
$723,571
|
$752,514
|
4.0%
|
Dana T. Aftab, Ph.D.
|
$560,000
|
$582,400
|
4.0%
|
Jeffrey J. Hessekiel, J.D.
|
$636,797
|
$662,269
|
4.0%
|
Amy C. Peterson, M.D. (1)
|
N/A
|
$640,000
|
N/A
|
Vicki L. Goodman, M.D. (2)
|
$650,000
|
$672,750
|
3.5%
|
Table of Contents
|
62
|
Exelixis, Inc.
|
NEO
|
2023 Bonus
Target
|
Michael M. Morrissey, Ph.D.
|
100%
|
Christopher J. Senner
|
50%
|
Dana T. Aftab, Ph.D.
|
50%
|
Jeffrey J. Hessekiel, J.D.
|
50%
|
Amy C. Peterson, M.D. (1)
|
50%
|
Vicki L. Goodman, M.D. (2)
|
50%
|
Table of Contents
|
Compensation of Executive Officers | Compensation Discussion and Analysis
|
2024 Proxy Statement
|
63
|
Corporate Goals
|
Weighting
(%)
|
NEO
|
Weighting
of
Corporate
Goals
|
Weighting of
Individual
Performance
Assessment
|
Cabozantinib
|
30%
|
Michael M. Morrissey, Ph.D.
|
100%
|
0%
|
Zanzalintinib
|
20%
|
Christopher J. Senner
|
70%
|
30%
|
XB002
|
15%
|
Dana T. Aftab, Ph.D.
|
70%
|
30%
|
XL102
|
5%
|
Jeffrey J. Hessekiel, J.D.
|
70%
|
30%
|
Clinical Collaborations
|
10%
|
Amy C. Peterson, M.D. (1)
|
70%
|
30%
|
Business Development
|
10%
|
Vicki L. Goodman, M.D. (2)
|
70%
|
30%
|
IND Candidates
|
5%
|
|||
New DCs
|
5%
|
|
||
Total
|
100%
|
Table of Contents
|
64
|
Exelixis, Inc.
|
PERFORMANCE OBJECTIVES
|
ACHIEVEMENTS
|
TARGET %
|
ACHIEVEMENT % (1)
|
Cabozantinib
|
30%
|
35%
|
|
Target
|
Maximum
|
||
Achieve up to three TLRs from
pivotal trials
|
Present up to two TLRs at
major medical meeting
|
›› Achieved four TLRs in cabozantinib pivotal
trials: CONTACT-03; CONTACT-02;
COSMIC-313 (second interim analysis of
OS); CABINET
›› Presented two TLRs at ASCO 2023
(CONTACT-03) and ESMO 2023 (CABINET)
|
|
Maximum Achievement
|
|||
Meet the cabozantinib
franchise net product
revenues target
|
Exceed 105% of the
cabozantinib franchise net
product revenue target in
the U.S.
|
›› Achieved just below the cabozantinib
franchise net product revenues target
|
|
Below Target Achievement
|
|||
Effectively prosecute and
assert the cabozantinib
patent estate against all
challengers
|
Favorably resolve litigation
with MSN Laboratories
Private Ltd. (MSN), resulting
in a loss of exclusivity for
cabozantinib no earlier
than 2030
|
›› Effectively prosecuted and asserted the
cabozantinib patent estate through and
beyond the October 2023 bench trial against
MSN and its affiliates
›› Settled litigation with Teva Pharmaceutical
Industries Limited (Teva) and its affiliates
|
|
Target Achievement
|
|||
Zanzalintinib
|
20%
|
13%
|
|
Target
|
Maximum
|
||
Achieve enrollment targets
for STELLAR-303 and
STELLAR-304 pivotal trials
|
Achieve additional
STELLAR-303 and
STELLAR-304
enrollment targets
|
›› STELLAR-303: Exceeded enrollment target.
›› STELLAR-304: Below enrollment target.
|
|
Below Target Achievement
|
|||
Initiate two new pivotal trials
|
Initiate three new
pivotal trials
|
›› Initiated one new pivotal trial (STELLAR-305)
|
|
Below Target Achievement
|
|||
XB002
|
15%
|
6%
|
|
Target
|
Maximum
|
||
Initiate cohort expansion
phase of ongoing Phase 1
JEWEL-101 trial and achieve
enrollment target
|
Achieve additional
JEWEL-101 enrollment
target
|
›› Initiated JEWEL-101 cohort expansion phase
›› Achieved near target enrollment
|
|
Below Target Achievement
|
|||
Expand one additional
JEWEL-101 cohort beyond the
initial protocol expansions
|
Expand two additional
JEWEL-101 cohorts
beyond the initial
protocol expansions
|
›› No JEWEL-101 cohorts expanded beyond
initial protocol expansions during 2023
|
|
Below Target Achievement
|
Table of Contents
|
Compensation of Executive Officers | Compensation Discussion and Analysis
|
2024 Proxy Statement
|
65
|
PERFORMANCE OBJECTIVES
|
ACHIEVEMENTS
|
TARGET %
|
ACHIEVEMENT % (1)
|
XL102
|
5%
|
4%
|
|
Target
|
Maximum
|
||
Complete dose escalation
of ongoing phase 1
QUARTZ-101, initiate cohort
expansion stage and
initiate one or more
combination cohorts)
|
N/A
|
›› Completed dose escalation of QUARTZ-101
|
|
Below Target Achievement
|
|||
Go/No-Go decision for
continuing development by
end of 2023.
|
Go/No-Go decision for
continuing development by
the third quarter of 2023
|
››Announced termination of XL102
development program in December 2023
|
|
Target Achievement
|
|||
Clinical Collaborations
|
10%
|
8%
|
|
Target
|
Maximum
|
||
Cybrexa Therapeutics
(CBX-12): Advance ongoing
CBX-12 phase 1 clinical trial
and begin enrolling dose-
expansion cohorts
|
CBX-12 opt-in decision
during 2023
|
›› CBX12-101 study advanced during 2023 with
focus on dose escalation
|
|
Below Target Achievement
|
|||
Sairopa B.V. (ADU-1805):
Submit IND for ADU-1805 to
FDA and advance program
into phase 1 clinical trial
|
ADU-1805 opt-in decision
during 2023
|
››IND clearance announced in February 2023,
and phase 1 trial is ongoing
|
|
Target Achievement
|
|||
Business Development
|
10%
|
3%
|
|
Target
|
Maximum
|
||
Complete three transactions
for oncology assets that are at
or near clinical stage
|
Complete four transactions
for oncology assets that are
at or near clinical stage and
two transactions for
preclinical oncology assets
or technology platforms
|
››Completed one transaction for oncology
assets at or near clinical stage
|
|
Below Target Achievement
|
|||
IND Candidates
|
5%
|
5%
|
|
Target
|
Maximum
|
||
Submit two new INDs to FDA
from either internal research
and development efforts or
existing/new collaborations
|
Submit three new INDs to
FDA from internal research
and development efforts or
existing/new collaborations
|
›› ADU-1805: IND clearance announced in
February 2023
›› XL309: Active IND in May 2023
|
|
Target Achievement
|
|||
New DCs
|
5%
|
6%
|
|
Target
|
Maximum
|
||
Advance three programs to
DC status
|
Advance five programs to
DC status
|
›› Declared and advanced four new DCs
|
|
Above Target Achievement
|
|||
100%
|
80%
|
Table of Contents
|
66
|
Exelixis, Inc.
|
Name
|
2023
Base
Salary
($)
|
2023
Target
Award
(%)
|
2023
Corporate
Performance
Weighting
(%)
|
2023
Approved
Corporate
Performance
(%)
|
2023
Individual
Performance
Weighting
(%)
|
2023
Individual
Performance
(%)
|
2023
Annual Cash
Bonus Payout
(% of Target
Award)
|
2023
Annual
Cash Bonus
Payout
($)
|
Michael M.
Morrissey, Ph.D.
|
$1,201,241
|
100%
|
100%
|
80%
|
N/A
|
N/A
|
80%
|
$960,993
|
Christopher J. Senner
|
$752,514
|
50%
|
70%
|
80%
|
30%
|
80%
|
80%
|
$301,006
|
Dana T. Aftab, Ph.D.
|
$582,400
|
50%
|
70%
|
80%
|
30%
|
150%
|
101%
|
$294,112
|
Jeffrey J. Hessekiel,
J.D.
|
$662,269
|
50%
|
70%
|
80%
|
30%
|
80%
|
80%
|
$264,908
|
Amy C. Peterson,
M.D. (1)
|
$640,000
|
50%
|
70%
|
80%
|
30%
|
80%
|
80%
|
$256,000
|
Table of Contents
|
Compensation of Executive Officers | Compensation Discussion and Analysis
|
2024 Proxy Statement
|
67
|
Table of Contents
|
68
|
Exelixis, Inc.
|
2023 Relative TSR Goal
|
||
Performance Level
|
Relative TSR Percentile v. Nasdaq
Biotechnology Index Companies
|
PSUs Vesting as a Percentage of Target
|
Below Threshold
|
49th percentile or below
|
0%
|
Threshold
|
50th percentile - 64th percentile
|
50%
|
Target
|
65th percentile - 79th percentile
|
100%
|
Maximum
|
80th percentile or above
|
175%
|
Table of Contents
|
Compensation of Executive Officers | Compensation Discussion and Analysis
|
2024 Proxy Statement
|
69
|
Name
|
Number of Shares
Subject to RSUs
|
Target Number of Shares
Subject to 2023 PSUs
|
Michael M. Morrissey, Ph.D.
|
313,185
|
313,185
|
Christopher J. Senner
|
85,414
|
85,414
|
Dana T. Aftab, Ph.D.
|
68,331
|
68,331
|
Jeffrey J. Hessekiel, J.D.
|
79,719
|
79,719
|
Amy C. Peterson, M.D. (1)
|
-
|
-
|
Vicki L. Goodman, M.D. (2)
|
82,566
|
82,566
|
Table of Contents
|
70
|
Exelixis, Inc.
|
Table of Contents
|
Compensation of Executive Officers | Compensation Discussion and Analysis
|
2024 Proxy Statement
|
71
|
Position
|
Ownership Level
|
Chief Executive Officer
|
NEW: Value equivalent to 6 times annual base salary
|
Other NEOs
|
Value equivalent to 3 times annual base salary
|
Table of Contents
|
72
|
Exelixis, Inc.
|
Misconduct
|
Material Harm
|
Commits a knowing violation
of a company policy or SEC
rules or regulations; or
Engages in the willful commission
of an act of fraud, dishonesty or
gross recklessness in the performance
or disregard of their duties
|
Misconduct contributes or could
reasonably be expected to
contribute to the material
harm of our business.
|
AND
|
|
Table of Contents
|
Compensation of Executive Officers | Compensation Discussion and Analysis
|
2024 Proxy Statement
|
73
|
Table of Contents
|
74
|
Exelixis, Inc.
|
Name and Principal
Position
|
Year
(1)
|
Salary
($)(2)
|
Bonus
($)(3)
|
Stock
Awards
($)(4)
|
Option
Awards
($)(5)
|
Non-Equity
Incentive Plan
Compensation
($)(6)
|
All Other
Compensation
($) (7)
|
Total
($)
|
||
Michael M. Morrissey,
Ph.D.
|
2023
|
1,192,001
|
-
|
14,259,313
|
-
|
960,993
|
11,000
|
16,423,307
|
||
President and Chief
|
2022
|
1,144,250
|
-
|
14,567,256
|
-
|
1,155,039
|
11,000
|
16,877,545
|
||
Executive Officer
|
2021
|
1,093,875
|
-
|
-
|
5,160,513
|
1,265,043
|
11,000
|
7,530,431
|
||
Christopher J. Senner
|
2023
|
746,726
|
-
|
3,888,899
|
-
|
301,006
|
11,000
|
4,947,631
|
||
Executive Vice
President
|
2022
|
716,172
|
-
|
4,093,312
|
-
|
361,786
|
11,000
|
5,182,270
|
||
and Chief Financial
Officer
|
2021
|
679,568
|
-
|
1,367,037
|
-
|
399,507
|
11,000
|
2,457,112
|
||
Dana T. Aftab, Ph.D.
|
2023
|
577,920
|
-
|
4,770,110
|
-
|
294,112
|
11,000
|
5,653,142
|
||
Executive Vice
President,
|
||||||||||
Discovery and
Translational
Research and Chief
Scientific Officer
|
||||||||||
Jeffrey J. Hessekiel, J.D.
|
2023
|
657,175
|
-
|
3,629,606
|
-
|
264,908
|
11,000
|
4,562,689
|
||
Executive Vice
President,
|
2022
|
630,285
|
-
|
3,656,426
|
-
|
318,399
|
11,000
|
4,616,110
|
||
General Counsel and
Secretary
|
2021
|
599,135
|
-
|
1,217,547
|
-
|
347,069
|
11,000
|
2,174,751
|
||
Amy C. Peterson, M.D.
|
2023
|
201,846
|
265,530
|
5,220,000
|
(8)
|
1,590,000
|
90,470
|
11,000
|
7,378,846
|
|
Executive Vice
President,
|
||||||||||
Product
Development &
Medical Affairs, and
Chief Medical Officer
|
||||||||||
Vicki L. Goodman, M.D.
|
2023
|
456,025
|
-
|
3,759,230
|
(9)
|
-
|
N/A
|
768,425
|
(10)
|
4,983,680
|
Former Executive
Vice President,
|
||||||||||
2022
|
622,500
|
500,000
|
4,687,500
|
(11)
|
-
|
325,000
|
11,000
|
6,146,000
|
||
Product
Development &
Medical Affairs, and
Chief Medical Officer
|
Table of Contents
|
Compensation of Executive Officers | Summary of Compensation
|
2024 Proxy Statement
|
75
|
Name
|
Payout of
RSUs Granted
in 2023
($)
|
Target Payout of
PSUs Granted
in 2023
($)
|
Maximum Payout
of PSUs Granted
in 2023
($)
|
Michael M. Morrissey, Ph.D.
|
6,100,844
|
8,158,469
|
14,277,302
|
Christopher J. Senner
|
1,663,865
|
2,225,035
|
3,893,811
|
Dana T. Aftab, Ph.D.
|
2,990,088
|
1,780,023
|
3,115,033
|
Jeffrey J. Hessekiel, J.D.
|
1,552,926
|
2,076,680
|
3,634,183
|
Amy C. Peterson, M.D.
|
5,220,000
|
-
|
-
|
Vicki L. Goodman, M.D.*
|
1,608,386
|
2,150,844
|
3,763,965
|
Table of Contents
|
Compensation of Executive Officers | Summary of Compensation
|
76
|
Exelixis, Inc.
|
Name
|
Payout of RSUs
Granted
in 2022
($)
|
Target Payout of
PSUs Granted
in 2022
($)
|
Maximum Payout
of PSUs Granted
in 2022
($)
|
Michael M. Morrissey, Ph.D.
|
5,597,591
|
8,969,665
|
15,696,906
|
Christopher J. Senner
|
1,572,890
|
2,520,422
|
4,410,714
|
Jeffrey J. Hessekiel, J.D.
|
1,405,013
|
2,251,413
|
3,939,933
|
Vicki L. Goodman, M.D.
|
4,687,500
|
-
|
-
|
Name
|
Threshold Payout of
PSUs Granted
in 2021
($)
|
Target Payout of
PSUs Granted
in 2021
($)
|
Maximum Payout
of PSUs Granted
in 2021
($)
|
Michael M. Morrissey, Ph.D.
|
1,600,637
|
4,268,393
|
8,536,786
|
Christopher J. Senner
|
512,633
|
1,367,037
|
2,734,073
|
Jeffrey J. Hessekiel, J.D.
|
456,567
|
1,217,547
|
2,435,094
|
Table of Contents
|
Compensation of Executive Officers | Summary of Compensation
|
2024 Proxy Statement
|
77
|
Estimated Future
Payouts Under
Non-Equity Incentive
Plan Awards (1)
|
Estimated Future
Payouts Under
Equity Incentive
Plan Awards (2)
|
All Other
Stock
Awards:
Number of
Shares of
Stock or
Units
(#)(3)
|
All Other
Option
Awards:
Number of
Securities
Underlying
Options
(#)(4)
|
Exercise
or Base
Price of
Option
Awards
($/Sh)
|
Grant Date
Fair Value
of Stock
and
Option
Awards
($)(5)
|
|||||
Name
|
Grant Date
|
Threshold
($)
|
Target
($)
|
Maximum
($)
|
Threshold
(#)
|
Target
(#)
|
Maximum
(#)
|
|||
Michael M.
Morrissey, Ph.D.
|
||||||||||
4/3/2023
|
-
|
-
|
-
|
-
|
-
|
-
|
313,185
|
-
|
6,100,844
|
|
4/3/2023
|
-
|
-
|
-
|
156,592
|
313,185
|
548,073
|
-
|
-
|
8,158,469
|
|
N/A
|
-
|
1,201,241
|
1,801,862
|
-
|
-
|
-
|
-
|
-
|
||
Christopher J.
Senner
|
||||||||||
4/3/2023
|
-
|
-
|
-
|
-
|
-
|
-
|
85,414
|
-
|
1,663,865
|
|
4/3/2023
|
-
|
-
|
-
|
42,707
|
85,414
|
149,474
|
-
|
-
|
2,225,035
|
|
N/A
|
-
|
376,257
|
620,824
|
-
|
-
|
-
|
-
|
-
|
||
Dana T. Aftab,
Ph.D.
|
||||||||||
1/3/2023
|
-
|
-
|
-
|
-
|
-
|
-
|
100,000
|
(6)
|
-
|
1,659,000
|
4/3/2023
|
-
|
-
|
-
|
-
|
-
|
-
|
68,331
|
-
|
1,331,088
|
|
4/3/2023
|
-
|
-
|
-
|
34,165
|
68,331
|
119,579
|
-
|
-
|
1,780,023
|
|
N/A
|
-
|
291,200
|
480,480
|
-
|
-
|
-
|
-
|
-
|
||
Jeffrey J.
Hessekiel, J.D.
|
|
|||||||||
4/3/2023
|
-
|
-
|
-
|
-
|
-
|
-
|
79,719
|
-
|
1,552,926
|
|
4/3/2023
|
-
|
-
|
-
|
39,859
|
79,719
|
139,508
|
-
|
-
|
2,076,680
|
|
N/A
|
-
|
331,135
|
546,372
|
-
|
-
|
-
|
-
|
-
|
||
Amy C.
Peterson, M.D.
|
||||||||||
8/24/2023
|
-
|
-
|
-
|
-
|
-
|
-
|
240,000
|
(7)
|
-
|
5,220,000
|
8/24/2023
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
160,000
|
21.75
|
1,590,000
|
N/A
|
-
|
106,667(8)
|
176,000(8)
|
(8)
|
-
|
-
|
-
|
-
|
-
|
|
Vicki L.
Goodman,
M.D. (9)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|||
4/3/2023
|
-
|
-
|
-
|
-
|
-
|
-
|
82,566
|
-
|
1,608,386
|
|
4/3/2023
|
-
|
-
|
-
|
41,283
|
82,566
|
144,490
|
-
|
-
|
2,150,844
|
|
N/A
|
-
|
325,000
|
536,250
|
-
|
-
|
-
|
-
|
-
|
Table of Contents
|
Compensation of Executive Officers | Summary of Compensation
|
78
|
Exelixis, Inc.
|
Table of Contents
|
Compensation of Executive Officers |Grants of Plan-Based Awards
|
2024 Proxy Statement
|
79
|
Table of Contents
|
80
|
Exelixis, Inc.
|
Option Awards(1)
|
Stock Awards(2)
|
||||||||
Name
|
Grant
Date
|
Number of
Securities
Underlying
Unexercised
Options
(#)
Exercisable
|
Number of
Securities
Underlying
Unexercised
Options
(#)
Unexercisable
|
Option
Exercise
Price
($)
|
Option
Expiration
Date
|
Number of
Shares or
Units of
Stock That
Have Not
Vested
(#)
|
Market
Value of
Shares or
Units of
Stock That
Have Not
Vested
($)(3)
|
Equity Incentive
Plan Awards:
Number of
Unearned
Shares, Units or
Other Rights
That Have Not
Vested
(#)
|
Equity
Incentive Plan
Awards:
Market or
Payout Value
of Unearned
Shares, Units
or Other
Rights That
Have Not
Vested
($)(3)
|
Michael M.
Morrissey,
Ph.D.
|
10/3/2017
|
480,000
|
24.41
|
10/2/2024
|
|||||
9/10/2018
|
308,365
|
18.80
|
9/9/2025
|
||||||
10/22/2020
|
94,003
|
(4)
|
2,255,132
|
94,002
|
(4)
|
2,255,108
|
|||
10/22/2020
|
94,003
|
(5)
|
2,255,132
|
||||||
3/4/2021
|
340,106
|
154,594
|
(6)
|
21.31
|
3/3/2028
|
||||
3/4/2021
|
250,374
|
(7)
|
6,006,472
|
||||||
3/4/2022
|
202,812
|
4,865,460
|
|||||||
3/4/2022
|
270,415
|
(8)
|
6,487,256
|
||||||
4/3/2023
|
313,185
|
|
7,513,308
|
||||||
4/3/2023
|
|
313,185
|
(9)
|
7,513,308
|
|||||
Christopher J.
Senner
|
10/3/2017
|
125,000
|
24.41
|
10/2/2024
|
|||||
9/10/2018
|
129,314
|
18.80
|
9/9/2025
|
||||||
9/11/2020
|
32,568
|
(4)
|
781,306
|
32,566
|
(4)
|
781,258
|
|||
9/11/2020
|
32,568
|
(5)
|
781,306
|
||||||
3/4/2021
|
32,076
|
769,503
|
|||||||
3/4/2021
|
80,186
|
(7)
|
1,923,662
|
||||||
3/4/2022
|
56,989
|
1,367,166
|
|||||||
3/4/2022
|
75,985
|
(8)
|
1,822,880
|
||||||
4/3/2023
|
85,414
|
2,049,082
|
|||||||
4/3/2023
|
85,414
|
(9)
|
2,049,082
|
||||||
Dana T. Aftab,
Ph.D.
|
10/3/2017
|
95,000
|
24.41
|
10/2/2024
|
|||||
9/10/2018
|
96,986
|
18.80
|
9/9/2025
|
||||||
9/11/2020
|
25,330
|
(4)
|
607,667
|
25,330
|
607,667
|
||||
9/11/2020
|
25,330
|
607,667
|
|||||||
3/4/2021
|
25,290
|
606,707
|
|||||||
3/4/2021
|
63,224
|
(7)
|
1,516,744
|
||||||
3/4/2022
|
44,618
|
1,070,386
|
|||||||
3/4/2022
|
59,490
|
1,427,165
|
|||||||
1/5/2023
|
100,000
|
(10)
|
2,399,000
|
||||||
4/3/2023
|
68,331
|
1,639,261
|
|||||||
4/3/2023
|
68,331
|
(9)
|
1,639,261
|
||||||
Table of Contents
|
Compensation of Executive Officers |Outstanding Equity Awards at Fiscal Year-End
|
2024 Proxy Statement
|
81
|
Option Awards(1)
|
Stock Awards(2)
|
||||||||
Name
|
Grant
Date
|
Number of
Securities
Underlying
Unexercised
Options
(#)
Exercisable
|
Number of
Securities
Underlying
Unexercised
Options
(#)
Unexercisable
|
Option
Exercise
Price
($)
|
Option
Expiration
Date
|
Number of
Shares or
Units of
Stock That
Have Not
Vested
(#)
|
Market
Value of
Shares or
Units of
Stock That
Have Not
Vested
($)(3)
|
Equity Incentive
Plan Awards:
Number of
Unearned
Shares, Units or
Other Rights
That Have Not
Vested
(#)
|
Equity
Incentive Plan
Awards:
Market or
Payout Value
of Unearned
Shares, Units
or Other
Rights That
Have Not
Vested
($)(3)
|
Jeffrey J.
Hessekiel, J.D.
|
10/3/2017
|
100,000
|
24.41
|
10/2/2024
|
|||||
9/10/2018
|
129,314
|
18.80
|
9/9/2025
|
||||||
9/11/2020
|
28,950
|
(4)
|
694,511
|
28,950
|
(4)
|
694,511
|
|||
9/11/2020
|
28,950
|
(5)
|
694,511
|
||||||
3/4/2021
|
28,568
|
685,346
|
|||||||
3/4/2021
|
71,418
|
(7)
|
1,713,318
|
||||||
3/4/2022
|
50,907
|
1,221,259
|
|||||||
3/4/2022
|
67,875
|
(8)
|
1,628,321
|
||||||
4/3/2023
|
79,719
|
1,912,459
|
|||||||
4/3/2023
|
79,719
|
(9)
|
1,912,459
|
||||||
Amy C.
Peterson, M.D.
|
8/24/2023
|
160,000
|
(11)
|
21.75
|
8/23/2030
|
|
|||
8/24/2023
|
240,000
|
(12)
|
5,757,600
|
Table of Contents
|
82
|
Exelixis, Inc.
|
Table of Contents
|
Compensation of Executive Officers |Outstanding Equity Awards at Fiscal Year-End
|
2024 Proxy Statement
|
83
|
Option Awards
|
Stock Awards
|
|||
Name
|
Number of
Shares
Acquired on
Exercise
(#)
|
Value
Realized on
Exercise
($)(1)
|
Number of
Shares
Acquired on
Vesting
(#)
|
Value
Realized on
Vesting
($)(2)
|
Michael M. Morrissey, Ph.D.
|
460,000
|
3,789,200
|
231,845
|
4,821,203
|
Christopher J. Senner
|
120,000
|
702,511
|
93,630
|
1,923,677
|
Dana T. Aftab, Ph.D.
|
82,500
|
227,702
|
69,260
|
1,432,063
|
Jeffrey J. Hessekiel, J.D.
|
97,500
|
412,508
|
79,674
|
1,645,833
|
Amy C. Peterson, M.D.
|
-
|
-
|
-
|
-
|
Vicki L. Goodman, M.D.
|
-
|
-
|
59,868
|
1,082,413
|
Table of Contents
|
84
|
Exelixis, Inc.
|
Table of Contents
|
Compensation of Executive Officers |Potential Payments Upon Termination or Change in Control
|
2024 Proxy Statement
|
85
|
Change in Control and Severance
Benefit Plan
|
Equity Plans
|
|||
Name
|
Benefit
|
Change in Control
Termination ($)(1)
|
Non-Change in
Control Termination
($)(2)
|
Certain
Change in
Control
Transactions
without
Termination
($)(3)
|
Michael M. Morrissey,
Ph.D.
|
Base Salary
|
2,402,482
|
1,801,862
|
-
|
Bonus
|
2,402,482
|
960,993
|
-
|
|
Vesting Acceleration (4)
|
36,109,081
|
-
|
36,109,081
|
|
COBRA Payments
|
60,230
|
45,172
|
-
|
|
Outplacement Services
|
50,000
|
-
|
-
|
|
Benefit Total
|
41,024,275
|
2,808,027
|
36,109,081
|
|
Christopher J. Senner
|
Base Salary
|
1,128,771
|
752,514
|
-
|
Bonus
|
564,386
|
301,006
|
-
|
|
Vesting Acceleration (4)
|
11,159,284
|
-
|
11,159,284
|
|
COBRA Payments
|
68,930
|
45,953
|
-
|
|
Outplacement Services
|
30,000
|
-
|
-
|
|
Benefit Total
|
12,951,371
|
1,099,473
|
11,159,284
|
|
Table of Contents
|
86
|
Exelixis, Inc.
|
Change in Control and Severance
Benefit Plan
|
Equity Plans
|
|||
Name
|
Benefit
|
Change in Control
Termination ($)(1)
|
Non-Change in
Control Termination
($)(2)
|
Certain
Change in
Control
Transactions
without
Termination
($)(3)
|
Dana T. Aftab, Ph.D.
|
Base Salary
|
873,600
|
582,400
|
-
|
Bonus
|
436,800
|
232,960
|
-
|
|
Vesting Acceleration (4)
|
11,210,527
|
-
|
11,210,527
|
|
COBRA Payments
|
53,308
|
35,539
|
-
|
|
Outplacement Services
|
30,000
|
-
|
-
|
|
Benefit Total
|
12,604,235
|
850,899
|
11,210,527
|
|
Jeffrey J. Hessekiel, J.D.
|
Base Salary
|
993,403
|
662,269
|
-
|
Bonus
|
496,702
|
264,908
|
-
|
|
Vesting Acceleration (4)
|
10,119,534
|
-
|
10,119,534
|
|
COBRA Payments
|
68,930
|
45,953
|
-
|
|
Outplacement Services
|
30,000
|
-
|
-
|
|
Benefit Total
|
11,708,569
|
973,130
|
10,119,534
|
|
Amy C. Peterson, M.D.
|
Base Salary
|
960,000
|
640,000
|
-
|
Bonus
|
480,000
|
85,333
|
(5)
|
-
|
Vesting Acceleration (4)
|
6,116,000
|
-
|
6,116,000
|
|
COBRA Payments
|
68,930
|
45,953
|
-
|
|
Outplacement Services
|
30,000
|
-
|
-
|
|
Benefit Total
|
7,654,930
|
771,286
|
6,116,000
|
|
Vicki L. Goodman, M.D.
(6)
|
Base Salary
|
-
|
672,750
|
-
|
Bonus
|
-
|
-
|
-
|
|
Vesting Acceleration (4)
|
-
|
-
|
-
|
|
COBRA Payments
|
-
|
4,675
|
-
|
|
Outplacement Services
|
-
|
-
|
-
|
|
Benefit Total
|
-
|
677,425
|
-
|
Table of Contents
|
Compensation of Executive Officers |Potential Payments Upon Termination or Change in Control
|
2024 Proxy Statement
|
87
|
Name
|
Vesting Acceleration Benefit
for Outstanding
PSUs Granted in 2020
($)
|
Vesting Acceleration Benefit
for Outstanding
PSUs Granted in 2021
($)
|
Vesting Acceleration Benefit
for Outstanding
PSUs Granted in 2022
($)
|
Michael M. Morrissey, Ph.D.
|
1,691,343
|
3,203,457
|
2,162,411
|
Christopher J. Senner
|
585,980
|
1,025,956
|
607,619
|
Dana T. Aftab, Ph.D.
|
455,738
|
808,943
|
475,722
|
Jeffrey J. Hessekiel, J.D.
|
520,871
|
913,779
|
542,774
|
Amy C. Peterson, M.D.
|
-
|
-
|
-
|
Vicki L. Goodman, M.D.
|
-
|
-
|
-
|
Table of Contents
|
88
|
Exelixis, Inc.
|
Table of Contents
|
Compensation of Executive Officers |Pay Versus Performance
|
2024 Proxy Statement
|
89
|
Value of Initial Fixed $100
Investment Based On:
|
Net Income
(millions)
($)
|
Net Product
Revenues
(millions)
($)(5)
|
||||||
Year
|
Summary
Compensation
Table Total for
PEO
($)(1)
|
Compensation
Actually Paid
to PEO
($)(1)(2)
|
Average
Summary
Compensation
Table Total for
Non-PEO NEOs
($)(1)
|
Average
Compensation
Actually Paid
to Non-PEO
NEOs
($)(1)(2)
|
Total
Stockholder
Return
($)(3)
|
Peer Group
Total
Stockholder
Return
($)(4)
|
||
2023
|
16,423,307
|
31,702,754
|
5,505,198
|
7,804,316
|
141
|
121
|
207.8
|
1,628.9
|
2022
|
16,877,545
|
16,020,538
|
5,149,608
|
5,038,751
|
94
|
116
|
182.3
|
1,401.2
|
2021
|
7,530,431
|
15,297,662
|
3,510,384
|
5,612,040
|
107
|
129
|
231.1
|
1,077.3
|
2020
|
2,349,812
|
18,565,411
|
1,237,199
|
5,878,678
|
118
|
129
|
111.8
|
741.6
|
Year
|
Summary Compensation
Table Total for PEO
($)
|
Exclusion of Stock Awards
and Options Awards for PEO
($)
|
Inclusion of Equity Values
for PEO
($)
|
Compensation Actually
Paid to PEO
($)
|
2023
|
16,423,307
|
(14,259,313)
|
29,538,760
|
31,702,754
|
Year
|
Average Summary
Compensation Table Total
for Non-PEO NEOs
($)
|
Average Exclusion of Stock
Awards and Options Awards
for Non-PEO NEOs
($)
|
Average Inclusion of Equity
Values for Non-PEO NEOs
($)
|
Average Compensation
Actually Paid to Non-PEO
NEOs
($)
|
2023
|
5,505,198
|
(4,571,569)
|
6,870,687
|
7,804,316
|
Year
|
Year End Fair
Value of Equity
Awards Granted
During Year That
Remained
Outstanding and
Unvested as of
Last Day of Year for
PEO
($)
|
Year over Year
Change in Fair
Value of
Outstanding and
Unvested Equity
Awards Granted
in Prior Years for
PEO
($)
|
Fair Value as of
Vesting Date of
Equity Awards
Granted and
Vested During Year
for PEO
($)
|
Year over Year
Change in Fair
Value of Equity
Awards Granted
in Prior Years that
Vested During Year
for PEO
($)
|
Fair Value at Last
Day of Prior Year
of Equity Awards
Forfeited During
Year for PEO
($)
|
Total - Inclusion
of Equity Values for
PEO
($)
|
2023
|
18,468,346
|
8,239,747
|
-
|
2,830,667
|
-
|
29,538,760
|
Table of Contents
|
90
|
Exelixis, Inc.
|
Year
|
Average Year End
Fair Value of Equity
Awards Granted
During Year That
Remained
Outstanding and
Unvested as of Last
Day of Year for
Non-PEO NEOs
($)
|
Average Year over
Year Change in Fair
Value of
Outstanding and
Unvested Equity
Awards Granted in
Prior Years for Non-
PEO NEOs
($)
|
Average Fair Value
as of Vesting Date
of Equity Awards
Granted and Vested
During Year for
Non-PEO NEOs
($)
|
Average Year over
Year Change in Fair
Value of Equity
Awards Granted in
Prior Years that
Vested During Year
for Non-PEO NEOs
($)
|
Average Fair Value
at Last Day of Prior
Year of Equity
Awards Forfeited
During Year for
Non-PEO NEOs
($)
|
Total - Average
Inclusion of Equity
Values for Non-PEO
NEOs
($)
|
2023
|
5,152,448
|
1,717,856
|
-
|
525,908
|
(525,525)
|
6,870,687
|
Table of Contents
|
Compensation of Executive Officers |Pay Versus Performance
|
2024 Proxy Statement
|
91
|
Table of Contents
|
92
|
Exelixis, Inc.
|
Relative TSR
|
Net Product Revenues
|
Table of Contents
|
Compensation of Executive Officers |Pay Versus Performance
|
2024 Proxy Statement
|
93
|
Table of Contents
|
94
|
Exelixis, Inc.
|
By Order of the Board of Directors
|
JEFFREY J. HESSEKIEL
|
Executive Vice President, General Counsel and Secretary
|
Alameda, California
|
April 18, 2024
|
Table of Contents
|
Householding of Proxy Materials
|
2024 Proxy Statement
|
95
|
Table of Contents
|
Table of Contents
|
Table of Contents
|
Table of Contents
|
Table of Contents
|
Table of Contents
|
Table of Contents
|
Table of Contents
|
Table of Contents
|
Table of Contents
|
Table of Contents
|